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ABSTRACT

Background: Prostate cancer is the second leading cause of death after lung cancer
among men in the US. The America Cancer Society predicts 164,690 new cases and 29,430
prostate cancer deaths in 2018. Of those diagnosed with prostate cancer, about 10-20 % will
develop castration-resistant prostate cancer (CRPC) within 5 years of diagnosis and 70 % of
those cases will metastasize to mCRPC. In 2014, nearly US $13.4 billion was spent on prostate
cancer in the US and expected to reach US $15.4 billion by 2020; making prostate cancer the
fifth most costly cancer.
Objective: To conduct a cost-effective analysis of enzalutamide, abiraterone plus
prednisone and cabazitaxel plus prednisone for the treatment of visceral mCRPC postdocetaxel failure from a US healthcare payer perspective utilizing life-time horizon Markov
model. These medications received highest National Comprehensive Cancer Network (NCCN)
guideline recommendation to treat visceral mCRPC post-docetaxel failure.
Methods: A pharmacoeconomic model was constructed using Microsoft Excel®
supported by visual basic codes and macros functions to estimate the cost-effectiveness [cost
per life year gained (LYG)] and cost-utility analyses [cost per quality adjusted life year
(QALY)] of visceral mCRPC therapies from a US healthcare perspective. We included direct
medical costs in the model expressed in 2018 US dollars. All model costs were adjusted for
v

inflation through the medical consumer price index (MCPI) as per the 1st quarter of 2018 and
future costs were discounted at 3 %, (i.e. drug costs, grade (≥3) adverse events that occurred at
least in 5 % of visceral mCRPC patients, costs of physician follow up, needed blood and
imaging investigations). We calculated overall survival (OS) and progression-free survival
(PFS) transition probabilities for each of the alternatives (abiraterone plus prednisone,
enzalutamide and cabazitaxel plus prednisone) from the Kaplan-Meier survival curves of phase
III trials using a digitizing program (Webplotdigitizer). Incremental cost-effectiveness ratios
(ICERs) [cost per life year gained (LYG)] and incremental cost-utility ratios (ICURs) [cost per
quality adjusted life year (QALY)] were calculated. Probabilistic sensitivity analysis was
conducted to assess the robustness of base-case analysis and provide cost-effectiveness
acceptability curve at various willingness-to-pay thresholds.
Results: Model results indicate (98.7 %) of patients who receive abiraterone acetate
plus prednisone, (83.8 %) who receive cabazitaxel plus prednisone and (86.8 %) who receive
enzalutamide are expected to die in 3 years. In 1.5 years’ time, patients who receive
enzalutamide will have significantly higher rates (14.47 %) of PFS than cabazitaxel plus
prednisone (0.27 %) and abiraterone acetate plus prednisone (0.51 %). Enzalutamide was
found to be more effective (1.58 LYG and 0.79 QALY) compared to abiraterone plus
prednisone (1.20 LYG and 0.58 QALY) and cabazitaxel plus prednisone (1.48 LYG and 0.56
QALY). Enzalutamide was also associated with lower total costs ($157,830) compared to
abiraterone acetate plus prednisone ($235,853) and cabazitaxel plus prednisone ($496,756).
Cabazitaxel plus prednisone had an ICER & ICUR of $931.7K/LYG and almost 13
million/QALY respectively when compared to the next lowest treatment, abiraterone acetate
plus prednisone.
Conclusion: Enzalutamide is cost-effective compared to abiraterone acetate plus
prednisone and cabazitaxel plus prednisone from a US healthcare perspective. Abiraterone
acetate plus prednisone is less effective and less costly compared to cabazitaxel plus
prednisone.
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CHAPTER 1: INTRODUCTION
Introduction
This chapter consists of four sections. First, we provide an overview of prostate
cancer, treatment of prostate cancer and castration resistant prostate cancer (CRPC). In
the second section, we discuss current therapeutic options used in metastatic castration
resistant prostate cancer (mCRPC). In the third section, we explore the importance of
conducting cost-effectiveness analysis (CEA) for healthcare and policy decision makers
as well as the significance of this study to the current literature. Finally, we discuss the
purpose of our study.
Overview of prostate cancer
Prostate cancer is the second leading cause of death after lung cancer among men
and the most common noncutaneous cancer affecting males in the United States (US).1,2
In 2016, 180,890 newly diagnosed cases and 26,120 prostate cancer deaths were
reported.2 The America Cancer Society (ACS) predicts 164,690 new cases and 29,430
prostate cancer deaths in 2018.3 Of those diagnosed with prostate cancer, about 10-20 %
will develop castration-resistant prostate cancer (CRPC) within 5 years of diagnosis and
70 % of those cases will metastasize to mCRPC.4–6
Prostate cancer creates a substantial medical and non-medical burden.7 In 2006,
nearly US $9.9 billion was spent on prostate cancer in the United States, increasing to US
$11.9 billion in 2012, US $13.4 billion in 2014 and expected to reach US $15.4 billion by
2020; making prostate cancer the fifth most costly cancer.7–9 There are several important
clinical and economic implications for utilizing newer therapeutic options that show
improved survival and minimize cost.
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Although annual incidence of low-risk prostate cancer decreased from 25,708 to
16,223 (37 % reduction) from 2004 to 2013, annual incidence of metastatic prostate
cancer increased from 1,685 to 2,890 cases during those years.10 Metastatic prostate
cancer cases were predominantly reported or diagnosed in men aged 55-69 years (92%).10
In addition, although age-adjusted mortality of prostate cancer has declined by 51 % from
1993-2014, there is evidence that decreasing death rates are due to increased public
awareness and earlier detection utilizing prostate specific antigen (PSA) screening and
digital rectal examination (DRE).11
The National Comprehensive Cancer Network (NCCN) guideline highly
recommends efficient use of PSA screening for early detection to decrease risk of overdetection and potential over-treatment while maintaining the reduction in age-adjusted
mortality due to prostate cancer.6
Several underlying mechanisms have been reported in the literature to better
inform healthcare providers about the pathogenesis of prostate cancer.12 These include
the ongoing androgen biosynthesis by the adrenal glands, upregulation of androgenic
receptors and prostatic tumor-mediated cytochrome P17 (CYP17), and the activation of
androgen receptors via different pathways.13,14 For the case of metastatic prostate cancer,
the mechanical theory and the seed-and-oil theory are two current theories that explain
how locally invasive prostate cancer becomes metastatic.12 The mechanical theory
attributes the spread of prostate cancer through the lymphatic system.12 Investigators or
proponents of the seed-and-oil theory believe that tissue factors facilitate the growth and
the spread of cancerous cells.12 Genetic variation and mutation, positive family history of
prostate cancer, diet and the use of 5-alpha reductase inhibitors for benign prostatic
2

hyperplasia (BPH) have been reported to be associated with causing high-grade
aggressive prostate cancer.15–17
The main indicators of prostate cancer prognosis are well described in the
literature. The first diagnostic indicator is the Gleason pattern. The Gleason Pattern is a
scoring system used to determine the aggressiveness of prostate cancer and assists in
choosing appropriate treatment options.18 The literature has also reported that three
consecutive increases in PSA levels after radiation therapy, or an increase in PSA level
by 0.2 ng/ml after radical prostatectomy may indicate metastasis.19 In addition,
performing biopsy and the clinical stage of prostate cancer may indicate failure of
localized prostate cancer treatment.19
Several organizations have issued screening guidelines for prostate cancer.
Examples of these organizations are the ACS, American Urological Association (AUA)
and NCCN. Although these organizations differ in their recommendation regarding PSA
routine testing, age groups, and life expectancy, they all agree on the importance of an
informed shared decision-making process that considers patient's values and preferences
and quality of life.6,20–23
PSA screening, accessing PSA velocity and measuring free versus bound PSA are
three different approaches used for detecting prostate cancer. Elevated PSA is
proportionally associated with higher odds of having prostate cancer.23 Assessing PSA
velocity is the second approach where the velocity is calculated by assessing three
consecutive PSA measurements over at least a period of 18-24 months.23 Free versus
bound PSA is another approach that is used to differentiate elevated PSA due to benign
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prostate hyperplasia (BPH) from cancer.24 A lower percentage of free PSA is associated
with higher chances of having prostate cancer.
Most prostate cancer patients are asymptomatic.25 Abnormal PSA level and/or
DRE are diagnostic measures used to identify prostate abnormality and/or cancer by
performing a biopsy.25 Usually, multiple biopsies are required since false-negative results
often happen.26 DRE helps in detecting nodules, asymmetry or differences in texture
which warrant the need for biopsy.26 Most prostate cancer patients have negative DRE
and elevated PSA.26 Cancer can also be recognized incidentally when resection is done to
manage BPH.26
Patients with advanced stages of prostate cancer may manifest skeletal
abnormalities due to bone metastases. Other manifestations include weight loss, anemia
and back pain due to spinal compression.25,27 In addition to PSA, DRE and performing
biopsy as part of diagnostic workup, kidney and liver function tests are also warranted in
advanced stages.24 Computed Tomography (CT) scan is also often required in case of
lymph node involvement.24
The American Joint Committee on Cancer (AJCC) issued a staging system for
prostate cancer based on Gleason score and grade group of staging.28 Generally, the
clinical staging of prostate cancer, PSA level, DRE findings, biopsy findings and imaging
study results indicate prostate cancer prognosis.28 The Tumor, Node and Metastases
(TNM) staging of prostate cancer is based on the extent of tumor size, involvement of
lymph nodes and whether the tumor is metastasized.
TNM staging helps physicians in determining not only the prognosis of the patient
but selecting the most appropriate therapy. This also helps patients in understanding their
4

disease condition and sharing their thoughts and decisions with the healthcare provider
regarding their disease condition and course of treatment.
Treatment of prostate cancer
Treating prostate cancer depends, as in other cancers, on disease prognosis and
staging. Current available therapeutic options are hormonal or androgen deprivation
therapy (ADT), radiation therapy, chemotherapy, radical prostatectomy, active
surveillance and watchful waiting.29 Other therapeutic options like whole-gland
cryotherapy or high-intensity focused ultrasound have not been studied well in terms of
survival benefit and rates of complications. AUA recommends considering the following
factors when treating prostate cancer: 1) patient preferences and values, 2) risk category
or staging of prostate cancer, 3) life expectancy, 4) post-treatment functional status 5)
baseline organ and overall health status. 29
Management of localized prostate cancer
Newly diagnosed prostate cancer patients are primarily treated with surgery
and/or radiation before they are put on hormonal therapy or ADT. Hormonal therapies are
usually considered if there are signs of recurrence like increased PSA levels and clinical
progression. The main goals of treatment are to prolong survival, prevent recurrence,
minimize complications and maintain patient quality of life.
Although localized prostate cancer is usually treated with ADT and radiation,
radical prostatectomy may be suitable in some cases. The AUA (2017) guideline
considers radical prostatectomy, radiation, and active surveillance as appropriate
therapeutic options to treat localized prostate cancer. However, the guideline
recommends patients be informed about potential therapeutic benefits and risks.30
5

Additionally, despite ADT being considered a therapeutic option for managing locally
advanced prostate cancer, AUA does not recommend it because it did not improve overall
survival and prostate cancer-specific survival in a large observational study that included
66,717 men with localized prostate cancer.30,31
In active surveillance, treatment or intervention is provided only if there are signs
of disease progression. According to NCCN, this includes low risk patients who have life
expectancy of ≥ 10 years, monitoring of PSA levels not more often than 6 months unless
clinically indicated, DRE not more often than 12 months unless clinically indicated and
performing biopsy every 12-24 months.32,33
Watchful waiting includes close-follow up and providing treatment based on
symptoms and is recommended in older patients with poor prognosis or life expectancy
of less than 10 years.33 In 2009, Lu-Yao et al concluded in the largest study in the US,
that the watchful waiting overall survival rate reached 94 % with men of median age 78
years.29 Since 1990, only two randomized clinical trials reported radical prostatectomy
compared to the watchful waiting approach in localized prostate cancer.34,35 The first one
was conducted in Sweden and concluded that surgery was able to prevent 6 % of prostate
cancer related deaths. In addition, prostate-specific mortality was 14.7 % compared to
20.7 % in the watchful waiting arm. However, the subsequent analysis did not show any
survival benefit for men over 65 years.34,35 Similar results were reported in the Prostate
Intervention Versus Observational Trial (PIVOT) randomized controlled trial that
included 731 men aged 75 years or younger with localized prostate cancer and life
expectancy of at least 10 years.36
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A sub-analysis conducted in the PIVOT study reported that men with PSA level
of at least 10 ng/ml at diagnosis had greater overall mortality reduction compared with
men with PSA level less than 10 ng/ml. Additionally, long-term follow-up data of PIVOT
reported that surgery did not reduce overall mortality compared to observation in patients
with localized prostate cancer (HR=0.84, P <0.06).36
Regarding advanced prostate cancer, both of the 2017 NCCN and 2011 European
association urology guidelines of managing advanced prostate cancer suggested the use
of luteinizing hormone releasing hormone (LHRH) agonists or antagonists, with or
without androgen blockage to manage advanced prostate cancer.32,37 They also
recommended performing bilateral orchiectomy in case of spinal compression. 32,37
Although current therapeutic options provided beneficial effects in reducing the
progression of prostate cancer and relieving potential obstructive symptoms, other toxic
adverse events were associated with the treatments. Thus, it is crucial to balance potential
benefits and risks before initiating treatment as well as considering patient's preferences,
values and quality of life. 6,20,21,23,38
Castration Resistant Prostate Cancer (CRPC)
In this section, we will discuss castration resistant prostate cancer (CRPC)
definition, types, diagnosis and treatment.
Castration resistant prostate cancer (CRPC) is a prostate cancer that is no longer
responding or refractory to hormone therapy. Thus, there is disease progression either in
rising PSA levels and/or clinical progression despite hormonal or ADT. 39,40
Patients with CRPC tend to have low testosterone levels classically below 50
pg/ml or even less than 20 pg/ml. Castration resistant prostate cancer can be non7

metastatic or metastatic (mCRPC).40 Non-metastatic form is usually called M0, whereas
metastatic form is called M1. About four to seven percent of living prostate cancer
patients in the European Union have M0. 40
In addition, CRPC is characterized by two to three consecutive elevated PSA
levels obtained at intervals of greater than 2 weeks and/or documented pathological
findings of disease progression on CT scan despite pharmacological (ADT) and surgical
interventions aimed to reduce testosterone levels.23,41
Castration is a treatment modality aimed at suppressing androgen production that
contributes to stimulating growth of prostate cancer cells. Metastatic CRPC (mCRPC)
mostly affects bones, and potential metastatic complications include skeletal-related
events, such as pathological fractures, pain and spinal cord compression which impairs
the quality of life of patients.41 Despite hormonal or ADT, of those diagnosed with
prostate cancer, about 10-20 % will develop castration-resistant prostate cancer (CRPC)
within 5 years of diagnosis and 70 % of those cases will metastasize to mCRPC. 4–6
Docetaxel
In 2004, docetaxel was introduced into the United States (US) market as the first
chemotherapeutic agent with survival benefit to treating mCRPC after failure of
traditional hormonal therapy or ADT.42 Two randomized clinical trials have shown that
docetaxel further improved survival in mCRPC despite known adverse events (e.g.
cardiovascular and gastrointestinal) that forced patients to stop therapy earlier.42 Both of
TAX327 trial and SWOG 99-16 trials showed higher survival rates with docetaxel
compared to prednisone plus mitoxantrone (17.4 vs. 16.5 months) and (17.5 vs 15.6
months) respectively.42
8

Our study focuses on evaluating current therapeutic options in the US market that
received the highest NCCN level of recommendation to treat visceral mCRPC patients
who progress after docetaxel treatment.6 Figure 1 demonstrates the 2017 NCCN
guidelines evidence blocks for managing mCRPC with visceral metastasis.6
Current therapeutic options of mCRPC
In the following discussion, we will explore current therapeutic options for
managing mCRPC following docetaxel therapy.
Cabazitaxel
In 2010, as a result of the TROPIC study, cabazitaxel with prednisone received
Food and Drug Administration (FDA) approval to treat visceral mCRPC for patients who
progress following docetaxel.
Cabazitaxel plus prednisone showed a median survival of 15.1 months compared
to 12.7 months with mitoxantrone plus prednisone. However, cabazitaxel plus prednisone
was associated with significant stage III/IV neutropenia and febrile neutropenia.43,44
Abiraterone
In 2011, abiraterone with prednisone was granted FDA approval to treat visceral
mCRPC. Abiraterone is a non-chemotherapeutic potent, selective, irreversible inhibitor of
CYP17A1 that inhibits androgen biosynthesis and thus inhibits androgenic signaling
which is important in the pathogenesis of mCRPC.13,14,20,45–47
Abiraterone plus prednisone approval was based on a large study that included
1195 men with CRPC treated with this combination. The median survival rate was 15.8
months for patients treated with abiraterone plus prednisone compared to 11.2 months for
placebo. Men who received abiraterone plus prednisone showed prolonged progression9

Figure 1*
NCCN guidelines for treating mCRPC 6

* Figure 1 [The figure describes NCCN guidelines for managing visceral mCRPC,
version 2. February 2017]
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free survival (PFS) rates, higher PSA response, and significantly longer time to PSA
progression.48,49
In 2012, abiraterone received an additional FDA approval to be used in visceral
mCRPC prior to receiving chemotherapy.45,49 Given its prolonged overall survival benefit
and convenient once-daily oral regimen, NCCN guidelines consider abiraterone plus
prednisone as one of the first-line therapeutic options for visceral mCRPC. However,
abiraterone is associated with serious cardiovascular disorders (i.e. cardiac arrhythmias,
ventricular fibrillation and cardiac arrest).48
Enzalutamide
In 2012, enzalutamide was approved by the FDA for visceral mCRPC patients
who progress despite docetaxel therapy. It works by inhibiting androgen receptors.50 In
2013, It received an additional FDA indication approval for treating visceral mCRPC in
chemotherapy-naïve patients. Enzalutamide prolonged survival relative to placebo in both
post-docetaxel and chemotherapy-naïve arms.51,52
In addition, enzalutamide showed better quality of life response, higher PFS rates
and longer time to develop skeletal manifestations. Enzalutamide showed 18-month
median survival compared to 13.6 months on prednisone alone. However, five cases (0.6
%) of seizure including one case of status epilepticus were reported. 51,52
Other therapeutic options
Sipuleucel-T and radium-223 were also introduced into the US market in 2010
and 2013 respectively and each agent showed a median survival benefit of 2-4 months
compared to control.45,53 Radium-223 which is a radioactive therapeutic modality that
received FDA approval based on ALSYMPCA trial (ALpharadin in SYMptomatic
11

Prostate CAncer) to treat mCRPC, symptomatic bone metastasis with no known visceral
metastasis.54,55 Results demonstrated higher survival rates compared to placebo (14.9 vs
11.3 months). However, both radium and sipuleucel have not been studied in patients
with visceral metastases.56 Thus, the 2017 NCCN guideline of prostate cancer does not
recommend either of both treatments to manage mCRPC with visceral metastasis.6
Radiation in metastatic prostate cancer
Radiation has been often used to treat metastatic prostate cancer in combination
with ADT. In a large study that included 6,382 men with newly diagnosed prostate
cancer, it was shown that combining both therapeutic modalities had better overall
survival (55 vs 37 months), and 5-year survival outcomes compared to ADT alone. 31
Additionally, radiation has been also used as a palliative therapeutic modality in patients
with mCRPC with painful bones, at higher risks of fractures and with patients with
impending spinal compression.57
Significance of CEA for healthcare and policymakers
In this section, we discuss the importance of conducting CEA for healthcare and
policymakers; and its role in introducing, assessing and maintaining health technologies.
CEAs in healthcare are conducted to provide decision makers with supplemental
information that may be helpful in supporting their decision about introducing,
maintaining, assessing or choosing the most cost-effective health technologies. CEAs
may provide comparative effectiveness, safety, cost and cost-effectiveness information
related to health technologies being considered or compared.
Based on 2017 NCCN guidelines of prostate cancer diagnosis and treatment, we
aimed to conduct a CEA from a US healthcare payer perspective utilizing life-time
12

horizon Markov model between enzalutamide, abiraterone plus prednisone and
cabazitaxel plus prednisone as they have the highest NCCN guideline recommendation to
be used in visceral mCRPC based on significant survival benefits conducted in clinical
trials.6 To our knowledge, no published study has conducted a CEA comparing these
therapies from a US healthcare payer perspective utilizing life-time horizon Markov
model. Thus, it would be informative for decision makers to estimate costs, outcomes and
cost-effectiveness between the three regimens by conducting CEA which assumes costs
are related to a single, common effect (i.e., cost/life-year gained) that may differ in
magnitude among alternative treatments or interventions.
Several organizations have utilized CEAs and health technology assessments to
better inform health and policymakers about the most cost-effective strategy.58,59 For
example, pharmaceutical companies submit drug dossiers that provide budget-impact
models and CEA studies to managed care organizations (MCOs) to facilitate formulary
decisions.58,59 In addition, in the UK, the National Institute of Clinical Excellence (NICE)
believes that providing clinical effectiveness data is not sufficient to introduce or
maintain health technology assessments (HTAs). Thus, there is a need to provide costeffectiveness data to facilitate decision making regarding an HTA.60,61
Although clinical evidence has been given the greatest weight by health
organizations and decision makers involved in resource allocation decisions, costeffectiveness analyses may also play an important role by decision makers in health and
medicine. For example, NICE has established procedures that incorporate the values of
patients and the public in their CEA submission requirements of HTA. NICE has also
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provided special consideration to end-of-life treatment and treatment for special
populations (e.g. elderly and children).62
Overall, economic evaluations provide useful tools that help in making decisions
about introducing or maintaining HTAs. Many world organizations and a few in the US
have offered recommendations on how to perform these evaluations and control the
growth of US health care expenditure in the future.63
The importance of the study to the literature
Since advanced stages of prostate cancer create substantial clinical and economic
burden to patients, healthcare providers, and policymakers, there is an important need to
conduct CEA comparing current therapeutic modalities that are used to treat visceral
mCRPC.7
We chose to conduct the study from a US healthcare perspective and not from
other perspectives (e.g. societal, patient or provider) for the following reasons. Studies
from societal perspective require that all medical, non-medical and non-healthcare sector
cost components be considered as recommended by the Second Panel of CostEffectiveness in Health and Medicine impact inventory.62 However, it is difficult to
obtain all cost components required to conduct the study from societal perspective.
The provider perspective was not considered as the US has a fragmented
healthcare system and different providers have different allocated budgets and lists of
covered formulary items by payers. Therefore, it is difficult to generalize our results for
different healthcare providers. Whereas, different US payers may use CEAs results as a
supplemental tool to decide on coverage/reimbursement decisions as results can be
utilized by any payer and results can be generalized to different US healthcare payers.
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Since clinical trials provide evidence regarding efficacy testing, there is still a
need to translate clinical effectiveness endpoints into measures that are valued and crucial
for different stakeholders.61 The results may provide physicians, decision makers and
healthcare payers valuable information to make appropriate treatment and payment
decisions.
We found several published CEAs or economic evaluation studies that either
evaluated different (from our proposed study) treatment regimens for mCRPC, utilized a
different methodology (e.g. decision tree model) to conduct the evaluation, stated a
different study perspective (e.g. societal), incorporated a shorter time horizon or were in
non-US setting.9,64–77
To our knowledge, no published study has conducted a CEA that compared
enzalutamide, abiraterone plus prednisone and cabazitaxel plus prednisone for the
treatment of visceral mCRPC from a US healthcare payer perspective utilizing life-time
horizon Markov model.6
The purpose of our study
The objective of our study is to conduct a CEA comparing enzalutamide,
abiraterone plus prednisone and cabazitaxel plus prednisone for the treatment of visceral
mCRPC post-docetaxel failure from a US healthcare payer perspective utilizing life-time
horizon Markov model. The results of this study may help in evaluating the cost
effectiveness between the different therapies. We considered these medication regimens
they have the highest NCCN guideline recommendation to be used in visceral mCRPC
based on significant survival benefits conducted in clinical trials.6
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CHAPTER 2: LITERATURE REVIEW
Introduction
This chapter is divided into four sections. We will discuss first the anatomy of
prostate gland, and the pathophysiology, epidemiology, etiology, prognosis, screening
and diagnostic workup of prostate cancer as well as the management of advanced and
metastatic castration resistant prostate cancer (mCRPC). In the second section, we will
explore CRPC and current therapeutic options used to treat visceral mCRPC. This will
include discussing the mechanism of action and pharmacokinetic profile of each
therapeutic option, approved indications and dosage, contraindications and precautions,
drug-drug interactions and dose adjustments, common side effects (>10%) and dosage
forms and pricing. In the third section, we will focus on economic studies’ methods,
requirements and compare decision-tree to Markov models. In the last section, we will
discuss the results of the literature review related to the economic evaluation of mCRPC.
Anatomy of the prostate gland
The prostate gland is surrounded by a capsule that is located below the bladder
and separated from the rectum by a layer of fascia named the denovillers aponeurosis.
Both of base of prostate gland and bladder are supplied by inferior vesicle artery.78 The
neurovascular bundle that lies on either side of the prostate is derived from the pelvic
plexus that is important for erectile function. These nerve plexuses arose from thoracic (T
10-12) and sacral (S 2-4) nerve roots. Figure 2 describes the anatomy of the prostate
gland.78
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Figure 2*
Anatomy of the prostate gland 78

*Figure 2 [Reproduced with permission from: Benway BM, Andriole GL. Prostate biopsy. In:
UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on [July 11, 2018].) Copyright
© 2018 UpToDate, Inc. For more information visit www.uptodate.com, see appendix for more
information]
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Pathophysiology of prostate cancer
Several underlying mechanisms have been reported by the literature to better
inform healthcare providers about the pathogenesis of prostate cancer.12 These include
the ongoing androgen biosynthesis by the adrenal glands, upregulation of androgenic
receptors and prostatic tumor-mediated cytochrome P17 (CYP17), and the activation of
androgen receptors via different pathways.13,14 Like other cancers, an imbalance between
rates of cell death and growth can lead to prostate cancer. 12 However, this transformation
is aggravated by subsequent gene mutations including the genes for retinoblastoma and
P53 which will eventually cause tumor progression and metastasis.12
Nearly 95 % of prostate cancer cases are adenocarcinomas, 4 % have transitional
cell morphology and are thought to arise from the urothelial lining of the prostatic urethra
and 1 % have squamous cell carcinomas.12 Although prostate cancer can arise either from
the peripheral zone (70%), central zone (15-20%), or transitional zone (10-15%), most of
prostate cancer cases involve multiple zones.12 When prostate cancer is locally invasive,
the transitional zone tumor cells spread to the bladder neck, whereas the peripheral zone
tumor cells spread into the seminal vesicles and ejaculatory ducts.12 For the case of
metastatic prostate cancer, the mechanical theory and the seed-and-oil theory are two
current theories that explain how locally invasive prostate cancer becomes metastatic.12
The mechanical theory attributes the spread of prostate cancer through the lymphatic
system. Investigators or proponents of the seed-and-oil theory believe that tissue factors
facilitate the growth and the spread of cancerous cells.12
Although screening and earlier prostate cancer detection reduce mortality, longterm treatment complications may offset treatment benefits. This may include bowel
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dysfunction, sexual and urinary complications which are common and long-lasting. For
example, nearly 50-70 % of patients that underwent radical prostatectomy suffer from
sexual impotence and about 40-50 % have urinary leakage.79–82
Epidemiology
Prostate cancer varies across geographical regions of the world, depending
primarily on different diagnostic workups than on known risk factors (i.e. diet, lifestyle,
race, age and androgen status).83 The following are the reported prostate cancer case rates
around the world: 104.2 cases of prostate cancer per 100,000 person-years in Australia
and New Zealand, 93.1 cases per 100,000 person-years in western Europe, 73.1 cases per
100,000 person-years in northern Europe, 85.6 cases per 100,000 person-years in North
America whereas the least is 7.2 cases per 100,000 person-years in Asia due to familial
and dietary factors.84 The age-adjusted mortality is the highest in Europe, 12 cases per
100,000 person-years and about 9.9 cases per 100,000 person-years in North America
due to inherent genetic variation, although further studies are needed to confirm the
underlying biological mechanism.84
Etiology
For many years, it was believed that testosterone which is a steroid hormone that
is produced mainly by the testes and adrenal cortex is responsible for prostate rapid
growth and cancer.40 African Americans have higher incidence of prostate cancer, and
studies had reported that African American men have 15 % higher levels of testosterone
compared to Hispanics and whites.85 However, a meta-analysis published by Boyle et al
in 2015 concluded that both endogenous and exogenous testosterone are not risk factors
for prostate cancer.86
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Rates of prostate cancer vary among different geographical areas across the
world, suggesting that genetic variation may be considered an important factor. For
example, the risk of prostate cancer tends to be higher among individuals with subSaharan African ancestry.15 Lower prostate cancer risks have been reported among native
Asians. However, US immigrant Asians tend to have higher risks of prostate cancer
compared to native Asians which suggests that diet and/or familial predisposition may be
contributing factors of prostate cancer.15
Positive family history of prostate cancer increases the risk of developing the
disease 6-7 years earlier than someone without a positive family history.16 Familial
predisposition is responsible for 5-10 % of prostate cancer cases.16 A positive BRCA-2
mutation may also increase the risk of developing aggressive prostate cancer at younger
age.16 The use of 5-alpha reductase inhibitor for the treatment of BPH has been also
attributed to increasing risks of developing aggressive high-grade prostate cancer
compared to placebo. In 2011, the food and drug administration (FDA) issued a box
warning for prescribing 5-alpha-reductase inhibitor products in patients with higher risks
of developing prostate cancer.15,17
Prognosis
The main indicators of prostate cancer prognosis have been well described in the
literature. The first diagnostic indicator is the Gleason pattern. The Gleason pattern is a
scoring system used to determine the aggressiveness of prostate cancer and assists in
choosing appropriate treatment options.18 Scores may range from 1 to 10 .18 Higher
Gleason Patten scores (>7) are suggestive of poorly differentiated prostate cancer cells
and/or poor prognosis.24 Gleason pattern scores between 1 and 6 indicates well20

differentiated or low-grade tumor. Scores of 7 are suggestive of moderately-differentiated
tumor.24 Additionally, nearly 30 % of localized prostate cancer will spread despite
treatment based on diagnostic PSA level, histologic grade and pathologic stage of the
tumor.18 Figure 3 demonstrates Gleason pattern for determining prostate cancer
prognosis. However, Gleason pattern scores have changed recently because scores of 2-5
are rarely seen. Other important indicators are age at diagnosis, capsular penetration and
the extent of tumor volume.24
The literature has also reported that three consecutive increases in PSA levels
after radiation therapy, or an increase in PSA level by 0.2 ng/ml after radical
prostatectomy may indicate metastasis.19 In addition, performing biopsy and the clinical
stage of prostate cancer may indicate failure of localized prostate cancer treatment.19
In a retrospective study that was conducted to evaluate the association of tumor
progression due to anesthesia after radical retropubic prostatectomies, 1642 procedures
were reviewed for patients who had general anesthesia and 1642 had opioid sparing
approach to anesthesia (neuraxial block). Results showed that patients who had general
anesthesia during prostatectomy had 30 % higher mortality risk and three times greater
risk of systemic progression.87,88
The Literature has also identified several biochemical and genetic markers that
help in determining the prognosis of prostate cancer. However, none of the following
genetic measures is routinely used in practice; mutations in MYC, P53, PTEN and ERGTMPRSS2 chromosomes.89
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Figure 3*
Gleason’s pattern of prostate cancer 90
ISUP Grade Group Classification System

*Figure 3 [Reproduced with permission from: Yang XJ. Interpretation of prostate biopsy. In:
UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on [July 11th, 2018].) Copyright
© 2018 UpToDate, Inc. For more information visit www.uptodate.com. See appendix for more
information]
22

Screening
Several organizations have issued screening guidelines for prostate cancer.
Examples of these organizations are the ACS, AUA and NCCN. Although these
organizations differ in their recommendation regarding PSA routine testing, age groups,
and life expectancy, they all agreed on the importance of an informed shared decisionmaking process that considers patient's value, preferences and quality of life. 6,20,21,23,38
Elevated PSA is proportionally associated with the odds of having prostate
cancer. When PSA level is 1ng/ml, prostate cancer is detected in 8 % of men. This
increases to 25 % if the PSA is between 4-10 ng/ml.21
The European Randomized Study of Screening for Prostate Cancer (ERSPC)
recommends that a PSA value of 3 ng/ml or higher warrants the need for lateralized
sextant biopsy.91 Preston et al published a study reporting the association of high PSA
levels in midlife and the odds of having deadly prostate cancer in the future.31,38 The
study included men, 40-59 years with PSA levels in the upper quartile versus those with
levels below the 50th percentile. The odds of having deadly prostate cancer was 8.7 if the
person is 40-49 years old, 12.6 if the person is 50-54 years old and 6.9 if the person is 5559 years old.38,91
ACS recommends average-risk men who are at the age of 50 receive information
about potential risks of prostate cancer and the importance of PSA screening. It further
recommends men having a positive family history, high risk men at age 45 and African
American men receive PSA screening. 2,21
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PSA retesting every 2 years is considered if PSA level falls below than 2.5 ng/ml.
However, annual retesting is required if PSA level is ≥ 2.5 ng/ml. 3,21
ACS recommends average-risk men who are at the age of 50 receive information
about potential risks of prostate cancer and the importance of PSA screening as well as
men having a positive family history, high risk men at age 45 and African.2,3,21AUA does
not recommend routine PSA testing for the following categories:23,92
1. Men over 70
2. Men under 40
3. Men who are 40-54 years old with average risk
4. Men with at least a life expectancy of 10-15 years
Conversely, the NCCN guideline is more conservative and recommends baseline
evaluation, physical examination and obtaining family history as well as baseline DRE
for patients who are 45-75 years.6 The published literature has also suggested other
approaches that may help in determining the likelihood of developing prostate cancer.
Assessing PSA velocity is the first approach where the velocity is calculated by assessing
three consecutive PSA measurements over at least a period of 18-24 months.23,92
Free versus bound PSA is another approach that is used to differentiate elevated
PSA due to benign prostate hyperplasia (BPH) from cancer.21,24 A lower percentage of
free PSA is associated with higher odds of having prostate cancer. The percentage is
calculated relative to total PSA level. Measuring free PSA levels would help physicians
to determine whether to perform a biopsy on a patient or not if PSA levels falls within 410 ng/ml. 21,24 This approach would also help in patients with either a large prostate gland
and in whom who had one biopsy with negative results.21,24 A percentage of free PSA
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more than 25 % considered normal. However, a biopsy is considered recommended if
free PSA level is below 18 % and others recommended a cutoff point of 12 %.21,24
Diagnostic workup
Most prostate cancer patients are asymptomatic.25 Abnormal PSA level and/or
DRE are diagnostic measures used to identify prostate abnormality and/or cancer by
performing a biopsy.25 Usually, multiple biopsies are required since false-negative results
often happen.26 DRE helps in detecting nodules, asymmetry or differences in texture
which warrantee the need for biopsy.26 Most prostate cancer patients have negative DRE
and elevated PSA.26 Cancer can also be recognized incidentally when resection is done to
manage BPH.26
Prostate cancer patients can also present with urinary retention, urinary frequency,
hematuria, adenopathy, bone pain, obstructive signs like decreased urine steam and overdistended bladder because of BPH.25 However, patients with advanced stages of prostate
cancer may manifest skeletal abnormalities due to bone metastases. Other manifestations
include weight loss, anemia and back pain due to spinal compression.25,27 In addition to
PSA, DRE and performing biopsy as part of diagnostic workup, kidney and liver function
tests are also warranted in advanced stages.24 Computed Tomography (CT) scan is also
often required in case of lymph node involvement.24
Tumor Node Metastases (TNM) Staging system of prostate cancer
The American Joint Committee on Cancer (AJCC) issued a staging system for
prostate cancer based on Gleason score and grade group of staging.93 Generally, the
clinical staging of prostate, PSA level, DRE findings, biopsy findings and imaging study
results indicate prostate cancer prognosis.6,25 The TNM staging of prostate cancer is
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described based on the extent of tumor size, involvement of lymph nodes and whether the
tumor is metastasized. The classification below helps physicians in determining not only
the prognosis of the patient but selecting the most appropriate therapy tailored for the
stage of prostate cancer. This may also help patients in understanding their disease
condition and share their thoughts and decisions with the healthcare provider regarding
the course of treatment.
TNM Staging of prostate cancer 93
A) T (primary tumor):

A) Nodal stages 93
NX
N0
N1

Regional lymph node metastasis
No regional lymph node metastasis
Metastasis in regional lymph node or nodes

B) Metastasis 93
M0
M1
M1a
M1b
M1c

No distant metastasis
Distant metastasis
Nonregional lymph node(s)
Bone(s)
Other site(s), with or without bone disease
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Management of advanced /metastatic prostate cancer
Both of 2017 NCCN and 2011 European association urology guidelines of
managing advanced prostate cancer suggested the use of LHRH agonists or antagonists,
with or without androgen blockage to manage advanced prostate cancer. They also
recommended performing bilateral orchiectomy in case of spinal compression.6,32,37
Although current therapeutic options provided beneficial effects in reducing the
progression of prostate cancer and relieving potential obstructive symptoms, other toxic
adverse events were associated with the treatments. Thus, it is crucial to balance potential
benefits and risks before initiating treatment as well as considering patient preferences,
values and quality of life.
The decision to start early hormonal treatment or defer treatment to later stage
was controversial until the Veterans Administration Cooperative Urology Research
Group (VACURG) recommended deferring hormone therapy until symptomatic
progression occurs to prevent early androgen resistance in prostate tumors.94–96 However,
several clinical trials have shown that starting early may reduce potential obstructive
complications and fractures.94,95
Advocates of intermittent ADT suggested this approach because of reduced
adverse events. However, Crook et al found that in randomized study that included 770
men who received intermittent therapy and 765 men who received continuous therapy
that intermittent approach is non-inferior to continuous in terms of overall survival and
was not as effective as continuous in patients with metastatic castration hormonesensitive prostate cancer (mCSPC). 95
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Combined androgen blockage therapy remains controversial because several
randomized clinical trials did not show survival benefits. However, a limited number of
studies reported a 3 to 6 month survival benefit with the use of complete androgen
blockage therapy.97 The number of negative studies was explained by the anti-androgen
withdrawal phenomenon where PSA levels are reduced when ADT is stopped because of
modifications in androgen’s receptors that facilitate tumor growth. Thus, many patients’
clinical condition was deteriorating because they did not stop ADT sooner. However,
based on survival benefits provided by some clinical trials, it was suggested by the
American Society of Clinical Oncology (ASCO) to consider combined androgen
blockage therapy in patients with hormonal sensitive and resistant prostate cancer
patients. Complete blockage of androgen receptors reduces symptoms of flare-ups (rise of
testosterone levels) that may happen with LHRH agonist treatment. Blockage approach
should be continued unless PSA progression occurs.31,97,98
In the following section, we will discuss CRPC and current therapeutic options
for mCRPC management. This will include discussing the mechanism of action and
pharmacokinetic profile of each therapeutic option, approved indications and dosage,
contraindications and precautions, drug-drug interactions and dose adjustments, common
side effects (>10%) associated with therapies; and dosage forms and pricing.
Castration Resistant Prostate Cancer (CRPC)
Newly diagnosed prostate cancer patients are usually treated with surgery and/or
radiation before they are put on ADT. Hormonal therapies (ADT) are usually considered
if there are signs of recurrence like increased PSA levels and clinical progression.
However, Castration Resistant Prostate Cancer (CRPC) happens when the patient is no
28

longer responding or refractory to hormone therapy. Thus, there is disease progression
either in rising PSA levels and/or clinical progression despite ADT.40
CRPC patients tend to have low testosterone levels classically below 50 pg/ml or
even less than 20 pg/ml. CRPC can be non-metastatic or metastatic. Non-metastatic form
is usually called M0, whereas metastatic form is called M1 or mCRPC. About four to
seven percent of living prostate cancer patients in the European Union have M0.40
CRPC is characterized by two to three consecutive elevation of PSA levels
obtained at intervals of greater than 2 weeks and/or documented pathological findings of
disease progression on CT scan despite pharmacological (ADT) and surgical
interventions aimed to reduce testosterone levels.20,41
Castration is a treatment modality aimed at suppressing androgen production that
contributes to stimulating growth of prostate cancer cells. Metastatic CRPC (mCRPC)
mostly affects bones, and potential metastatic complications include skeletal-related
events, such as pathological fractures, pain and spinal cord compression which impairs
the quality of life of patients.20,41
Main goals of treatment are prolonging survival, preventing recurrence,
minimizing complications and maintaining patient quality of life. Despite ADT, most
prostate cancer patients (70 %) will develop mCRPC in their lifetime. Thus, starting
docetaxel would be warranted in these cases as a first line treatment for managing
mCRPC.4–6
ACS predicts there are about 12-29 million of prostate cancer survivors living in
the US. 40 It is also expected that there is about half a million non-metastatic prostate
cancer patients in the US. 40 Clinicians should evaluate how risky the disease condition is
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and how long it will take the patient to progress into metastatic stage. PSA doubling time
and absolute PSA levels are critical indicators of disease progression. PSA doubling time
is defined as the time needed for PSA level to increase by 100 % in the blood. The longer
the duration is, the better the prognosis the patient has. If the PSA doubling time falls less
than 10 months, the worse the prognosis the patient has.40
Figure 4 describes CRPC current therapeutic options indications, route and
schedule of administration, contraindications, use of steroids and survival information.
Until February 2018, there were no FDA approved novel therapeutic agents to treat nonmetastatic CRPC and patients were treated with ADT alone.39,99 However, apalutamide
received FDA approval to treat non-metastatic CRPC patients based on a randomized
double-blind multicenter trial that included 1,207 patients. About 401 patients received
ADT alone and 806 patients received apalutamide 240 mg orally plus ADT. The main
efficacy outcome was to assess metastasis free-survival (MFS). Results showed that
patients who received apalutamide and ADT had longer survival duration compared to
ADT alone (40.5 months vs. 16.5 months).39,99
All therapeutic options displayed in figure 4 are indicated for metastatic stages of
CRPC except for apalutamide which is indicated for non-metastatic stage. All therapeutic
options are given in conjunction with ADT. However, both abiraterone and docetaxel
may be combined with ADT when cancer is disseminated. Additionally, patients who
have higher risks of developing metastasis based on clinical and/or PSA progression may
be started on enzalutamide, apalutamide and ADT.43,45,51,100–103
Many important factors play a role in determining the course of treatment. This includes
site and rate of disease progression, patient preference, route of administration,
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Figure 4*
Current therapies for CRPC 43,45,51,100–103

*Figure 4 [ Reproduced with permission from: Dawson NA. Overview of the treatment of

castration-resistant prostate cancer (CRPC). In: UpToDate, Post TW (Ed), UpToDate, Waltham,
MA. (Accessed on [Date].) Copyright © 2018 UpToDate, Inc. For more information visit
www.uptodate.com, see appendix.]
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side effects profile, drug-drug interaction, regulatory and reimbursement statuses.104 The
site of metastatic involvement is the most crucial factor that affects survival in CRPC
patients.105 This was based on a large meta-analysis that included 8,820 men in different
phase III clinical trials. Overall survival was the highest (31.6) months among men with
only lymph node involvement. Survival decreased significantly among patients who had
bone (21.3 months), lung (19.4 months) or liver (13.5 months) metastasis.105
In addition to site involvement, the presence of visceral metastasis, poor
performance status, use of opioids, presence of circulating tumor cells, increased PSA,
alkaline phosphatase (ALK) and lactic dehydrogenase (LDH) levels as well as low
hemoglobin and serum albumin levels are all considered factors that affect survival
among CRPC patients.106 Several phase III clinical trials evaluated survival rates in
patients who progress despite docetaxel treatment. Results showed that patients had
longer overall survival rates when low number of serum circulating tumor cells was
detected (<5 cells per 7.5 ml).107–109
Bone biomarkers have been also used to assess survival rates in patients with
mCRPC since bone resorption and formation processes are disrupted in metastatic
patients. Higher levels (>50th percentile) of bone resorption and formation markers like
N-telopeptide, pyridinoline, C-terminal collagen propeptide and bone alkaline
phosphatase were associated with poorer prognosis and shorter overall survival (22
months vs. 15 months) compared with patients with normal biomarkers level.110
Overall treatment goals for patients with bone metastasis include improving
mobility, pain control and preventing complications such as spinal compression and
pathological fractures.
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Radiation has been used extensively in patients with bone metastasis as a pain reliever
since it provides benefit in 80-90 % of cases.104
The literature identified other therapeutic options that are used for mCRPC.
Sipuleucel-T and radium-223 were introduced into the US market in 2010 and 2013
respectively and both showed a median survival benefit of 2-4 months compared to
control.45,53 Radium-223 is radiopharmaceutical agent that improve patient quality of life
by providing pain relief, improving overall survival and reducing complications. Radium223 received FDA approval based on ALSYMPCA trial (ALpharadin in SYMptomatic
Prostate CAncer) to treat mCRPC, symptomatic bone metastasis with no known visceral
metastasis.54,55 Results demonstrated higher survival rates compared to placebo (14.9 vs
11.3 months). However, since both radium and sipuleucel have not been studied in
patients with visceral metastases, the 2017 NCCN guideline of prostate cancer does not
recommend either of both treatments to manage mCRPC with visceral metastasis.6
Therapeutic options of visceral mCRPC
In this section, we will discuss NCCN highest level of recommendation therapies
to treat visceral mCRPC.
Abiraterone (Zytiga®) 104
It inhibits the biosynthesis of androgens in both testicles and androgen gland
tissues by irreversibly inhibiting CYP17. Thus, it inhibits precursors of testosterone
formation like dehydroepiandrosterone (DHEA) and androstenedione. It is metabolized
by the liver and mostly excreted by feces (88 %). Abiraterone has a relatively a long halflife (14.4-16.5 hours) that is prolonged in case of liver failure. Abiraterone is indicated in
both mCRPC and Castration Sensitive Prostate Cancer (CSPC). Unlike castration
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resistant, CSPC is the initial phase of advanced prostate cancer where the disease is still
sensitive to lowering testosterone levels or hormonal therapy.
Abiraterone has a convenient once daily regimen of 1,000 mg. It is given in
combination with 10 milligrams (mg) of prednisone for mCRPC. However, a lower dose
(5 mg) of prednisone is given for CSPC.
Abiraterone significantly interacts with CYP3A4 inducers. It is recommended to
double the dose of abiraterone when a strong CYP3A4 inducer is concomitantly given
with abiraterone. There is no dose adjustment required in case of renal impairment.
However, a dose of 250 mg orally once daily is given if the patient has moderate liver
failure (child-pugh class B).
Abiraterone is contraindicated in pregnant and breast-feeding women, severe liver
failure (child-pugh class C) and when AST and/or ALT increases (>5) times during
treatment. If the patient had (> 5) times the upper limit of AST and/or ALT, it is
recommended to withhold the treatment until liver function tests return to normal, then
reinitiate with 750 mg orally daily. If this continues, a dose reduction to 500 mg is
required. Discontinuation of therapy is warranted if hepatotoxicity happens at a dose of
500 mg. In addition, since abiraterone is hepatotoxic, significant increases in liver
function tests have been reported in the first 3 months of treatment. Therefore, liver
functions are measured at baseline, every 2 weeks for 3 months then monthly. Patient
may also develop significant hypertension as a result of CYP17 inhibition. Additionally,
the drug is associated with risks of infections and adrenocortical insufficiency. Table 1
describes common side effects (≥ 10 %) associated with abiraterone use.
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Table 1
Common side effects (of any grade) of abiraterone 104
Cardiovascular
Central
nervous system
Endocrine &
metabolic

Hypertension (9% to 37%), edema (25% to 27%)
Fatigue (39%), insomnia (14%)

Hypertriglyceridemia (63%), hyperglycemia (57%), hypernatremia (33%),
hypokalemia (17% to 30%), hypophosphatemia (24%), hot flash (15% to
22%)
Gastrointestinal Constipation (23%), diarrhea (18% to 22%), dyspepsia (6% to 11%)
Genitourinary
Urinary tract infection (7% to 12%)
Hematologic & Lymphocytopenia (20% to 38%; grades 3/4: 4% to 9%), bruise (13%)
oncologic
Hepatic
Increased serum ALT (11% to 46%), increased serum AST (15% to 37%),
increased serum bilirubin (7% to 16%)
Neuromuscular Joint swelling (30%), myalgia (26%)
& skeletal
Respiratory
Cough (7% to 17%), upper respiratory infection (5% to 13%), dyspnea
(12%), nasopharyngitis (11%)
Abiraterone is available as 500 mg tablets. However, in May 2018, FDA
approved a dosage form of 125 mg tablets (Yonsa®) yet not available in the US market
(at the time of writing this thesis). The Average Wholesale Price (AWP) of one box
(60’s) of abiraterone 500 mg is US $12,278.59.
Enzalutamide (Xtandi®) 104
Enzalutamide works by causing cellular death and reduction in tumor prostate
volume through inhibiting DNA binding and nuclear translocation. Enzalutamide is
primarily metabolized by the liver CYP2C8. In addition, it is mainly excreted by urine
(71 %) and feces (14%). The prodrug half-life is 5.8 days whereas the terminal half-life
of the metabolite N-desmethyl is 7.8 to 8.6 days.
A dose of 160 mg of Enzalutamide orally once daily is indicated for mCRPC. In
July 2018, enzalutamide received an additional FDA indication to be used for non-
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metastatic CRPC patients. The approval extends the indication for the oral therapy, which
was previously approved for men with mCRPC.
Major drug-drug interactions are with CYP2C8 and CYP3A4 substrates.
Enzalutamide is also an inducer of CYP2C19 and 2C9. However, no dose adjustment is
required either in renal or hepatic impairment. Since enzalutamide is associated with risks
of neurotoxicity, discontinuation of therapy is warranted in case of seizure. In addition,
enzalutamide is contraindicated in pregnancy and breast-feeding women. The drug
should be given with caution in the following conditions; posterior reversible
encephalopathy syndrome, patients with predisposing risks for seizure or
spermatogenesis as it may impair male fertility. Table 2 describes the most common side
effects (>10%) associated with enzalutamide. The AWP of one box (120’s) of
enzalutamide 40 mg is US $13086.23.
Table 2
Common side effects (of any grade) of enzalutamide 104
Cardiovascular
Central nervous
system
Endocrine &
metabolic
Gastrointestinal
Hematologic &
oncologic
Neuromuscular &
skeletal
Respiratory

Peripheral edema (12% to 15%), hypertension (6% to 14%)
Fatigue (≤51%), falling (5% to 13%), headache (11% to 12%),
dizziness (10% to 11%)
Hot flash (15% to 20%), weight loss (11% to 12%)
Constipation (13% to 23%), diarrhea (12% to 22%), decreased
appetite (19%), nausea (14%)
Neutropenia (15%; grades 3/4: 1%)
Weakness (≤51%), back pain (19% to 29%), arthralgia (21%),
musculoskeletal pain (15% to 16%)
Upper respiratory tract infection (11% to 16%), dyspnea (11%)
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Cabazitaxel (Jevtana®) 104
Cabazitaxel is a taxane derivative that inhibits microtubule depolymerization and
cell division. Therefore, it causes cell apoptosis and inhibits tumor proliferation.
Cabazitaxel is metabolized by the liver CYP3A4,3A5 and has a terminal half-life of 95
hours. Cabazitaxel is given in combination with prednisone for mCRPC patients. The
guideline recommends a dose of 25 mg/m2 once every 3 weeks (in combination with
prednisone).
CYP3A inhibitors interact significantly with cabazitaxel. Thus, it is highly
recommended to avoid this combination since it increases cabazitaxel concentration. If
this combination cannot be avoided, a dose reduction of cabazitaxel by 25 % is required.
Cabazitaxel does not require dose adjustment in mild to moderate renal failure.
However, it is recommended to use the drug with caution in patients with severe renal
impairment (CrCl <15 ml/min). The use of cabazitaxel is contraindicated in severe
hepatic failure (total bilirubin >3 times Upper Limit of Normal (ULN)), pregnancy,
breast-feeding and neutrophil counts of ≤ 1,500 cells/mm3. It is also recommended to use
the drug with caution in the following conditions: elderly patients with moderate renal
failure, severe hepatic failure, neutropenia and pancytopenia, GI toxicity, hypersensitivity
reactions, pulmonary toxicity, renal failure and urinary disorders. Therefore, it is
recommended to monitor CBC, differential, platelet count at baseline and during
treatment as clinically indicated. Table 3 describes the most common side effects (>10%)
that are associated with cabazitaxel. The AWP of 60 mg/1.5 mL injection (1.5 mL) of
cabazitaxel is US $12573.32.
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Table 3
Common side effects (of any grade) of cabazitaxel 104
Central nervous system
Gastrointestinal

Genitourinary
Hematologic &
oncologic

Neuromuscular &
skeletal
Respiratory
Miscellaneous

Fatigue (25% to 37%), peripheral neuropathy (13%; grades 3/4:
<1%), peripheral sensory neuropathy (7% to 11%; grades 3/4: <1%)
Diarrhea (27% to 47%), nausea (25% to 34%), vomiting (15% to
22%), constipation (18% to 20%), decreased appetite (13% to 19%),
abdominal pain (6% to 17%), anorexia (16%), dysgeusia (7% to
11%)
Hematuria (14% to 21%), urinary tract infection (7% to 11%)
Anemia (98% to 100%; grades 3/4: 10% to 14%), leukopenia (80%
to 96%; grades 3/4: 29% to 69%), neutropenia (3% to 94%; grades
3/4: 2% to 87%), thrombocytopenia (35% to 48%; grades 3/4: 3% to
4%)
Weakness (15% to 20%), back pain (11% to 16%), arthralgia (7% to
11%)
Dyspnea (5% to 12%), cough (6% to 11%)
Fever (5% to 12%)

In the following section of this chapter, we will discuss economic studies’
methods and requirements as well as compare decision-tree analysis to a Markov model
analysis.
Pharmacoeconomic studies methods 111–117
There are four main methods of pharmacoeconomic studies. Each of the following

discussed method measures cost in monetary terms but differs regarding how health
outcomes are measured and compared.
Cost-Minimization Analysis (CMA) is used when two medical interventions are
comparable in effects but differ in cost. This analysis allows for the identification of the
least costly alternative. For example, CMA may be used to compare the value of two
generic medications rated as equivalent by FDA, but the cost varies due to different
pricing.
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Cost-Effectiveness Analysis (CEA) assumes costs are related to a single, common
effect (i.e., cost/life-year gained) that may differ in magnitude among alternative
treatments or interventions. CEA is widely used because outcomes are easy to quantify
when compared to different pharmacoeconomic analyses types (e.g. CUA, CBA).
However, CEA would not be appropriate to use when different units are used (e.g. blood
glucose level versus prothrombin time). Clinicians, patients and decision-makers may
decide on which agent is cost-effective based on the value differences of outcomes.
Cost-Utility Analysis (CUA) uses the same method as cost-effectiveness but is
wider in scope, as it incorporates patient preferences into the cost model. This patient
preference is called utility, which is expressed as cost/quality-adjusted life-year (QALY)
gained. CUA measures outcomes based on years of life adjusted by utility weights which
range from (0.0-1.0) where “1” indicates perfect health and “0” indicates death. Although
some researchers consider CUA as a subset of CEA, there is no agreement on how to
measure utility weights.
Cost-Benefit Analysis (CBA) is an economic comparison between two
interventions that requires the conversion of all effect inputs (for example, reduced
hospitalization) into monetary outputs, which helps to allocate health care resources.
Both benefits and costs are measured in monetary terms which help clinicians and
decision makers determine whether the benefits of an intervention exceed implementation
costs. Thus, it helps in comparing different programs or interventions with similar or
unrelated outcomes by predicting whether the dollar value of the added outcomes exceeds
the cost required to obtain those outcomes.

39

Requirements of pharmacoeconomic studies
Jolicoeur et al (1992) had suggested the following requirements for a welldesigned pharmacoeconomic analysis: define the problem, identify the study’s
perspective, determine outcomes and alternatives, select the appropriate method, place
monetary values on the outcomes, identify study resources, establish outcomes
probabilities, conduct decision analysis, perform sensitivity or incremental cost analysis
or discounting and finally presenting the results with any limitations.117
Identifying the study’s perspective (patient, payer, societal) is essential in any
pharmacoeconomic study because results of evaluation depends heavily on the
perspective taken. For example, alteplase may be of best-value from a societal
perspective since it can cause 1 % reduction in mortality rates in a large population.
However, streptokinase (cheaper option) may represent a better value from a hospital
perspective because it provides similar outcomes for a cheaper price.
Patient perspective evaluates costs from the perspective of patients, what they pay
for a product or service not covered by insurance. This may include copayments and outof-pocket costs. This perspective may be considered when we assess the impact of drug
therapy on patient quality of life.
Provider perspective evaluates actual costs of providing a service or a product
regardless of what the provider charges. Providers can be Managed-Care Organization
(MCO), hospitals or private-practice physicians.118
Payer perspective includes but is not limited to insurance companies, government
or the employer. Payer perspective considers costs allowed or reimbursed by the payer.
However, societal perspective is the broadest one because it is the only one which
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considers the benefit of a product or service to the society. Societal perspective is mostly
used in countries with nationalized medicine since it includes all direct and indirect costs
in the economic evaluation. 118
Discounting is another requirement of an economic evaluation with a time period
longer than 1 year since there is a time value associated with money, and costs are
estimated based on money spent or saved in future years. A 3-5 % is a generally accepted
discount rate for healthcare interventions. However, it is recommended to conduct
sensitivity analysis by including higher and lower estimates of various discount rates to
account for variability.62,118
Time-horizon is another requirement to consider when conducting an economic
evaluation because it should be long enough to reflect all important differences in outcomes
and costs between comparisons. Time-horizon basically depends on the natural history of
disease and the study objective.62
Sensitivity analysis is also important because it allows us to determine how results
vary over a relevant range of values. Sensitivity analysis produces unbiased estimates of
cost-effectiveness mean.62 It identifies sources of parameter uncertainty, characterize
uncertainty as probability distribution (e.g. beta & gamma distributions) and propagate it
through model simulation providing robust analysis.118 The following discussion will
compare decision-tree analysis to Markov model.
Decision-Tree Analysis 119–121
Decision-tree analysis is the process of systematically comparing different
decision options by displaying choices that helps in calculating values needed to compare
these options. Decision analysis helps in determining which option is more cost-effective
41

when decisions are complex, and uncertainty of information exists. Decision analysis
starts with identifying the objective, perspective and duration of study. Second, specific
alternatives should be selected for comparison (e.g. intervention versus no intervention,
old versus new drug). Third, a decision structure analysis is drawn to represent either of
the choices (e.g. treatment A versus B), chances (e.g. probability of adverse events due to
different therapeutic options) and final outcomes of each option of interest. Fourth,
obtained data of probabilities and costs are specified on the decision-tree and calculations
are performed to estimate the Incremental Cost-Effectiveness Ratio (ICER) or
incremental net-benefit ratio. Since some uncertainty surrounds the estimates, it is
important to perform sensitivity analysis in the final step by including the highest and
lowest range of probabilities and costs in the decision-tree to obtain the lower and higher
range of answers.
Markov model 120,122
Unlike decision-tree, Markov model is used to present complex scenarios with
longer follow-up periods that occur over several repetitive intervals, or cycles. Markov
model helps in situations where patients move back and forth, or between different health
status over periods of time. We used Markov model to answer our research questions
since cancer patients move into different health status based on their disease condition
(e.g. progression-free survival, progression or death) where death is an absorbing stage
where patient cannot move into any different health state later.
Markov model starts with determining different health situations a patient may
experience (Markov states) where a patient cannot be in different health status at the
same time. Second, all possible transitions between different health statuses are
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determined based on obtained clinical data. Third, number and length of cycles are
determined based on the disease status being evaluated. For example, for chronic
diseases, a cycle length of 1 year is commonly used. Fourth, the proportion of patients
who are likely to move from one health status to another during each cycle is determined
based on provided clinical data. This is followed by calculating costs and outcomes in the
fifth step. For example, percentage of patients who stay alive after cycle 1 get a value of
1 if the outcome of interest is years of life gained or saved. The total costs and outcomes
are then summed for all cycles.
Costs are incorporated in any cost-effectiveness decision analytic method.
Drummond et al has proposed in his book Methods for the Economic Evaluation of
Health Care Programmes (3rd ed.) the following four categories of costs: health care
sector costs, costs to other sectors, patient and family costs, and productivity costs.
However, the literature has also reported different classification of costs known as direct
medical and non-medical indirect; indirect costs; and intangible costs. Direct medical
costs include but not limited to costs of medications, monitoring, administration,
counseling, diagnostic tests, hospitalization, emergency visits, home medical costs and
ambulance services. Indirect medical costs include travel costs to receive healthcare
treatment, hotel stay for patient or family for out of town care and non-medical assistance
related to a condition like home-making services. Indirect costs may include loss of
productivity of patient, caregiver and due to premature mortality. Intangible costs may
include but not limited to costs due to feeling pain, anxiety and fatigue.123 The following
section will explain results of the literature review related to economic evaluation of
mCRPC.
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Results of the literature review related to economic evaluations of mCRPC
We conducted a systematic review using PubMed to identify published economic
evaluations and CEAs/CUAs of current therapeutic agents which received highest
recommendation by the NCCN to treat visceral mCRPC patients. The medical subject
headings (MeSH) terms (((("Prostatic Neoplasms"[Mesh]) AND "Neoplasm
Metastasis"[Mesh]) OR "secondary" [Subheading]) AND "Cost-Benefit
Analysis"[Mesh]) OR "Quality-Adjusted Life Years"[Mesh] were used to identify
relevant articles. Subheadings included cost-effectiveness and cost-utility analyses as
well as published economic evaluations. Limitations were given for gender since prostate
cancer affects males, human and articles published in English in the last 10 years since all
medications of interest were introduced in the last 10 years. No additional limits were
applied to the search strategy. The next page describes the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram that discusses the
process of articles selection.
No studies were identified that conducted an economic evaluation of abiraterone
acetate, enzalutamide and cabazitaxel to treat visceral mCRPC patients’ refractory to
docetaxel therapy from a US healthcare payer perspective utilizing life-time horizon
Markov model. However, several economic evaluations compared different treatment
paradigms for mCRPC, or had a different perspective (e.g. societal), or targeted different
patient population, or utilized a different methodology (e.g. decision tree model) to
inform decision makers or had a shorter time-horizon or were in non-US settings. 9,64–77
In addition, to our knowledge, our study is the first one that evaluated the above
mentioned therapeutic agents from a US healthcare payer perspective.
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Identification

PRISMA Flow Diagram*

Records identified through
database searching
(n = 2,957)

Additional records
identified through other sources
(n = 154)

Records screened
(n = 3,106)

Records excluded/
Irrelevant to prostate
cancer
(n =2,958)

Full-text articles assessed
for eligibility
(n = 148)

Included

Eligibility

Screening

Records after duplicates removed
(n = 5)

Studies included in
the literature review
(n = 97)

Our focus:
CEA/Economic evaluation
articles (n=16)

Full-text articles excluded,
with reasons
(n = 51)
1. Radiation therapy (n=6)
2. Surgical proctectomy
(n=5)
3. Screening/detection (n=18)
4. Localized cancer (n=7)
5. Hormone dependent (n=4)
6. Non-prostate specific
(n=3)
7. Outcomes/Adverse events
(n=4)
8. Non-drug related/Imaging
study (n=1)
9. Non-cancer related (n=4)

Efficacy/effectiveness/safety/
review /non-economic (n= 81)

* From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting
Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement. PLoS Med 6(7): e1000097.
doi:10.1371/journal. pmed1000097
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The following discussion will explore published economic evaluations that
included abiraterone plus prednisone, cabazitaxel plus prednisone and/or enzalutamide
for the treatment of visceral mCRPC.
Abiraterone acetate
Ramaekers el al (2017) published an Evidence Review Group (ERG) perspective
of the NICE single technology appraisal of abiraterone acetate as a treatment option of
mCRPC among chemotherapy naïve patients.110 The manufacturer Janssen was invited
by NICE to submit evidence for clinical efficacy and cost-effectiveness of abiraterone
acetate with prednisone compared to watchful waiting for chemotherapy naïve patients
with mCRPC. The purpose was to evaluate whether the use of abiraterone acetate
followed by docetaxel is more effective than watchful waiting followed by docetaxel.64
Both Maastricht University Medical Center and Kleijnen Systematic Reviews Ltd
(KSR) were commissioned as an ERG. The main aim was to develop a NICE guidance
by the appraisal committee for the use of abiraterone acetate plus prednisone to treat
mCRPC in England and Wales since COU-302-AA clinical trial results for this group of
patients were not presented. The ERG concluded in its final guidance that abiraterone
acetate is a therapeutic option to treat mCRPC among chemotherapy naïve patients.
Although the CEA of abiraterone was evaluated for mCRPC in this study, the population
of interest were patients who did not receive chemotherapy before. In addition, it did not
include enzalutamide and cabazitaxel in its comparison. 64
Gong et al (2014) evaluated the CEA of abiraterone and sipuleucel-T in
asymptomatic mCRPC using a Markov model from a US societal perspective. However,
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the population of interest were patients who did not receive docetaxel (chemotherapy).65
In addition, sipuleucel is not indicated for visceral mCRPC.45,53
Dellis et al (2014) had published a review article of economic evaluation of
abiraterone acetate in mCRPC. The review mostly discussed previous work of prostate
cancer economics, clinical efficacy of available therapeutic options, safety profile and
budgetary impact of abiraterone. However, non-of the selected articles in that review
conducted a comparative CEA of abiraterone plus prednisone, enzalutamide and
cabazitaxel plus prednisone for visceral mCRPC.67
Wilson et al (2014) evaluated the CEA of cabazitaxel, enzalutamide and
abiraterone acetate compared to placebo for the treatment of mCRPC. However, the
authors utilized a decision-tree model to conduct the analysis over 18 months (short timehorizon). The CEA was conducted from a US societal perspective and no discounting has
been used due to short-time horizon.68
Zhong et al (2013) evaluated the CEA of abiraterone, cabazitaxel, mitoxantrone
and prednisone for mCRPC treatment in the US. The aim was to compare abiraterone and
cabazitaxel to two placebos (prednisone and mitoxantrone). However, the analysis
included different treatment modalities, utilized a decision-tree model from a US societal
perspective and had a relatively short time-horizon (18 months).66
Dyer et al (2012) had published a NICE guidance of abiraterone acetate for
mCRPC patients who progress despite docetaxel therapy. Clinical efficacy and cost
effectiveness data of abiraterone were submitted by the manufacturer Janssen, UK that
received evaluation by an ERG. COU-AA-301 trial compared abiraterone acetate plus
prednisone to placebo with prednisone in patients who progress despite docetaxel
47

therapy. The main end-point was median overall survival over 12.8 months whereas
secondary end-points were decline in progression-free survival (PFS) and PSA
concentration. Abiraterone provided higher overall survival rates (14.8 vs. 10.9 months),
prolonged PFS and reduced PSA concentration compared to placebo. The committee
recommended abiraterone as a therapeutic option for mCRPC patients who progress
despite docetaxel therapy.124
Pollard et al (2016) conducted a CEA of abiraterone, sipuleucel-T, enzalutamide,
docetaxel, radium-223, and cabazitaxel for the treatment of mCRPC. However, the
authors included chemotherapy naïve patients and treatments which are not indicated for
visceral mCRPC like radium-223 and sipuleucel-T. They also utilized a decision-tree
model to calculate the ICER from a US societal perspective.69
Pilon et al (2016) evaluated the cost per median overall survival month of
abiraterone and enzalutamide for the treatment of mCRPC using three published phase III
clinical trials data. Therefore, it was not a head-head study. Median treatment duration for
patients who received enzalutamide was 18 months, whereas median treatment duration
for patients who received abiraterone was 14 months. Overall median follow-up time of
abiraterone was 49.2 months and 31 months for enzalutamide. Results showed that
median overall survival of abiraterone plus prednisone was 34.7 months and 35.3 months
for enzalutamide. The cost per median overall survival month was calculated by dividing
the treatment cost by number of months needed to achieve overall survival for each
treatment. Overall costs per median overall survival month and phase III clinical trials
outcomes were lower with abiraterone plus prednisone compared to enzalutamide ($3231
versus 4512; 28% reduction).70
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Massoudi et al (2017) evaluated associated incremental costs of enzalutamide
versus abiraterone plus prednisone for the treatment of chemotherapy-naïve patients with
mCRPC from a US payer perspective. They calculated the number needed to treat and
associated costs of both treatments required to obtain an additional patient free of
progression, chemotherapy or death over a year time-horizon. Clinical outcomes were
obtained from COU-AA-302 and PREVAIL clinical trials. Main end-points were
progression-free survival, time to initiate chemotherapy and overall one-year survival.
Associated costs were calculated as number needed to treat multiplied by the difference
in cost per treated patient. Results showed that enzalutamide is cost-effective compared
to abiraterone for treating chemotherapy naïve patients with mCRPC.71
Restelli et al (2017) had explored the economic burden of mCRPC in Italy. The
authors investigated all patients affected by mCRPC and treated with a single agent in an
annual time horizon. Direct costs included adverse reactions, medications (abiraterone,
enzalutamide, cabazitaxel and radium-223) and skeletal related event management (bony
metastasis). They calculated associated costs per patient per year and multiplied it by
number of patients with mCRPC in Italy. Nearly €196-228 millions of direct medical
costs were associated with mCRPC in Italy mostly attributed to the cost of treatment.72
Peters et al (2016) evaluated the cost-effectiveness of radium-223 compared to
abiraterone, cabazitaxel and enzalutamide for patients with mCRPC refractory to
docetaxel from a Dutch societal perspective. Efficacy, safety and skeletal related event
data were obtained from indirect treatment comparison. Authors utilized a life-time (5
years) Markov model to conduct the CEA using a specific Dutch resource use and costs
for mCRPC. A time horizon of 5 years was employed, which can be considered lifetime,
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given the short life expectancy of the patient population. Radium-223 was associated
with lower costs (€6092 and €4465) and higher quality-adjusted life years (QALY) 0.02
and 0.01 compared to abiraterone and cabazitaxel respectively. However, radium-223
was associated with lower QALY (-0.06) and lower life-time costs (€7390) compared to
enzalutamide. Authors concluded that radium-223 is a less costly agent and offering
comparable health benefits compared to abiraterone, enzalutamide and cabazitaxel for the
treatment of mCRPC from a Dutch societal perspective. However, radium-223 is not
indicated to treat visceral mCRPC. 73
Dragomir et al (2014) estimated drug costs of LHRH, denosumab, abiraterone and
cabazitaxel for the management of mCRPC from a Quebec public healthcare system
(Canada) perspective over a period of 28 months using a Markov model. The mean costs
were C$48,428 per patient (95% CI: C$47,624 to C$49,232). Costs increased
significantly to C$104,071 (95% CI: C$102,373 - C$105,770) per patient when
abiraterone was given before docetaxel therapy. It was predicted that the annual drug
costs for a cohort of 4,000 mCRPC patients in Canada is C$193.6 - C$416.3 million.74
Finally, Sorensen et al (2013) evaluated the budgetary impact of abiraterone
acetate plus prednisone for mCRPC patients from a US healthcare payer perspective. The
authors utilized a decision-tree model to compare treatment costs of mCRPC before and
after docetaxel adoption based on a hypothetical 1,000,000 member-plan. The analysis
concluded that abiraterone has a neutral impact on US health plan budget due to small
number of eligible prostate cancer patients and lower toxicity-related costs compared
with docetaxel.9
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Our literature review included 13 articles that had abiraterone acetate as part of
the economic evaluation for patients with mCRPC. Two of the 12 articles were ERG
perspective of a NICE single technology appraisal. Three were for chemotherapy naïve
patients with mCRPC. Nine included different treatment paradigms. One was a review
article. One was a budget impact analysis. Three utilized a decision-tree model and had a
short-time horizon (≤18 months). Five were evaluated from a societal perspective. Two
were in a non-US setting. One had a life-time horizon (5 years). One was evaluated from
a US healthcare payer perspective.
In summary, the review of abiraterone acetate economic evaluation included only
two articles that were similar to our research question. Wilson et al (2014) conducted
CEA of abiraterone, enzalutamide and cabazitaxel. However, it had a short-time horizon
(18 months), utilized a decision-tree model with no discounting and included only the
cost of major side effects.68 Although Peters et al (2016) included the three therapies of
interest in addition to radium-223 which is not indicated to treat visceral mCRPC, it
utilized a Markov model and had a life-time horizon (5 years). However, it was a Dutch
economic evaluation from a societal perspective.73
Cabazitaxel
In addition to the above discussed articles that included cabazitaxel (7 out of 13)
articles as part of abiraterone acetate economic evaluation of mCRPC, the literature also
identified the following two articles of cabazitaxel economic evaluation.
Kearns et al (2017) published an ERG perspective of the NICE single technology
appraisal of cabazitaxel as a treatment option of mCRPC. The manufacturer Sanofi, UK
was invited by NICE to submit clinical efficacy and cost-effectiveness data of cabazitaxel
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for the treatment of mCRPC for patients who already received chemotherapy (docetaxel).
The school of health and related research appraisal group at the University of Sheffield
were commissioned as an independent ERG.75
Clinical efficacy data were derived from the TROPIC phase III clinical trial which
compared cabazitaxel plus prednisone to mitoxantrone plus prednisone (placebo).
Abiraterone plus prednisone, enzalutamide and radium-223 were further identified by
NICE final scope for the subgroup of people with bone metastasis only. However,
patients with visceral metastasis were not included.
Network meta-analysis (NMA) was conducted to create clinical evidence since no
direct comparison of abiraterone or enzalutamide has been conducted with cabazitaxel.
Cabazitaxel showed improved median overall survival and PFS compared to
mitoxantrone (placebo). However, the NMA did not indicate any statistically significant
differences among abiraterone, cabazitaxel and enzalutamide for both overall survival
and PFS. The ERG recommended cabazitaxel as a treatment option of mCRPC for
patients who progress despite docetaxel therapy.122
Flannery et al (2017) had conducted a budget impact analysis for the use of
cabazitaxel for the treatment of mCRPC refractory to docetaxel therapy. Authors aimed
to estimate one-year projected budget impact of using cabazitaxel as a second-line option
for mCRPC following docetaxel therapy utilizing a hypothetical one million members of
US private managed care plan. The model included radium-223, abiraterone acetate,
cabazitaxel and enzalutamide with utilization rates derived from market research data.
Both major side effects and treatment costs were incorporated into the model. Authors
concluded that cabazitaxel may be a cost-saving therapeutic option to the health plan.76
52

Enzalutamide
In addition to the above discussed articles that included enzalutamide (9 out of
15) articles as part of abiraterone acetate and/or cabazitaxel economic evaluation of
mCRPC, the literature also identified the following article of enzalutamide economic
evaluation.
Bui et al (2016) evaluated the budget impact analysis of enzalutamide among
chemotherapy naïve patients with mCRPC from a US payer perspective. A model was
developed using a hypothetical one million-member US plan over one-year time horizon.
The model included the cost of treatment and side effects of abiraterone acetate, radium223, sipuleucel-T and docetaxel. Different sources of data were utilized to obtain costs of
treatment, administration and monitoring, adverse events and rates of chemotherapy
naïve mCRPC patients. The budget impact analysis included the calculation of the
incremental aggregate budget impact, per patient per year (PPPY), per patient per month
(PPPM) and per member per month (PMPM). Results showed that adopting enzalutamide
in a population of 115 chemotherapy-naïve mCRPC patients would have an annual
incremental budget impact of $510,641 ($4,426 PPPY, $369 PPPM, and $0.04 PMPM).77
Overall, since additional discussed articles did not conduct a CEA of the three
therapies of visceral mCRPC from a US healthcare perspective utilizing life-time Markov
model in the US setting; our economic evaluation will add to the previously published
economic evaluations in this therapeutic area.
In summary, this chapter provided a detailed review of prostate cancer disease
condition, screening, diagnosis, treatment, CRPC, therapeutic options of mCRPC,
pharmacoeconomic studies’ methods and requirements, compared decision-tree to
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Markov model and discussed the results of literature review related to economic
evaluation of mCRPC.
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CHAPTER 3: METHODS
Introduction
In this chapter we discuss methods used to estimate the cost-effectiveness [cost
per life year gained (LYG)] and cost-utility analyses [cost per quality-adjusted life-year
(QALY)] comparing abiraterone acetate plus prednisone, enzalutamide and cabazitaxel
plus prednisone in visceral mCRPC patients who progress despite docetaxel
chemotherapy from a US healthcare payer perspective using a life-time horizon Markov
model. The first section will discuss the research design. The second section will discuss
the pharmacoeconomic model used in the study. This includes study comparators,
population, time horizon, study perspective, discounting, transition probabilities,
effectiveness measures, cost measures, adverse events and the calculation of an
Incremental-Cost-Effectiveness Ratio (ICER) and an Incremental-Cost-Utility Ratio
(ICUR). The third section will discuss probabilistic sensitivity analysis. In the last
section, we will discuss human subjects’ approval to conduct this study.
Research design
In this section, we will provide an overview of the research design. Our research
design is a pharmacoeconomic model that was constructed using Microsoft Excel® and
supported by visual basic codes and macros functions to estimate the cost-effectiveness
[cost per LYG] and cost-utility analyses [cost per QALY] comparing abiraterone acetate
plus prednisone, enzalutamide and cabazitaxel plus prednisone in visceral mCRPC
patients who progress despite docetaxel chemotherapy from a US healthcare payer
perspective using life-time horizon Markov model.
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CEA assumes costs are related to a single, common effect (i.e., cost/life-year
gained) that may differ in magnitude among alternative treatments or interventions. CEA
is widely used because outcomes are easy to quantify when compared to different
pharmacoeconomic analyses types (e.g. CUA, CBA). Clinicians, patients and decisionmakers may decide on which agent is cost-effective based on the value differences of
outcomes.111–117
CUA uses the same method as cost-effectiveness but is wider in scope, as it
incorporates patient preferences and quality of life into the cost model. This patient
preference is called utility, which is expressed as cost/QALY gained. CUA measures
outcomes based on years of life adjusted by utility weights which range from (0.0-1.0)
where “1” indicates perfect health and “0” indicates death.111–117
Model description
A life-time horizon Markov chain model was constructed from a US healthcare
perspective using Microsoft Excel® and supported by visual basic codes and macro
functions for a hypothetical cohort of visceral mCRPC patients who progress despite
docetaxel therapy to receive either of abiraterone plus prednisone, enzalutamide and
cabazitaxel plus prednisone based on 2017 NCCN highest level of recommendation for
treating visceral mCRPC after docetaxel chemotherapy.
A three-health state [Progression-Free Survival (PFS), progression and death]
transition model reflecting survival was developed as illustrated in Figure 5. The patient
who starts in the PFS health state may stay in the same health state until the next cycle,
progress to another state or die. However, a patient with disease progression may either
stay in the same state until the next cycle, improve and go back to the PFS state, or die.
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Figure 5
Health states transition model of a mCRPC patient
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Cohort simulation was conducted for a hypothetical cohort of visceral mCRPC
patients starting in the same health states. At each cycle, transition probabilities were
applied. The proportion of patients in each cycle was calculated and summed using
matrix algebra. Since mCRPC disease management and complications develop at a
relatively fast time scale, a cycle of 7 days length was considered for cost-effectiveness
modeling of mCRPC therapies.73,125
Since we are conducting an economic evaluation in the oncology setting, our
approach allowed us to model overall-survival (OS) and PFS in a manner that reflected
COU-AA-301 trial which compared abiraterone plus prednisone to placebo (prednisone),
AFFIRM trial which compared enzalutamide to placebo and TROPIC trial which
compared cabazitaxel plus prednisone to mitoxantrone plus prednisone (placebo).43,48,51
Since phase III clinical trials do not provide survival information beyond the data
horizon, modeling OS and PFS using clinical trials data provided the transition
probabilities of the different health states for a mCRPC patient reflecting primary sources
of survival evidence provided by the clinical trials.43,48,51
We calculated OS and PFS transition probabilities for each of the alternatives
(abiraterone plus prednisone, enzalutamide and cabazitaxel plus prednisone) from the
Kaplan-Meier survival curves of phase III trials using a digitizing program
(Webplotdigitizer).126 Additionally, to generalize the findings from the trials and
extrapolate survival beyond the data horizon, Weibull parametric modeling techniques
were applied to approximate OS and PFS for abiraterone plus prednisone, enzalutamide
and cabazitaxel plus prednisone for each cycle within the model’s time horizon. Weibull
parametric modeling was applied because it visually provided the best fit survival
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distribution data beyond clinical trials survival information. Additionally, this was
supported by analysis of variance results (ANOVA) results of R2 and sum square of
statistics for OS and PFS. Both gompertz and exponential distribution curves did not fit
extrapolated survival data. The Weibull equation for estimating survival is: S(t) = e-ℷ t γ,
where S(t) is the estimate of the survivor function at time (t), lambda (ℷ) the scale
parameter, and gamma (γ) the shape parameter.127
Weibull distribution data of OS and PFS were then incorporated into the Markov
model for each therapy. The proportion of dead individuals were calculated by
subtracting OS from one (1-OS). Proportion of individuals with disease progression were
calculated by subtracting 1 from the sum of proportion of dead and progression free
survival patients [i.e. 1- (death+PFS)].
A 3% discounting rate was applied for all patients who survived (PFS and
progressed patients) after the first year (52 weeks) as recommended by the US Panel on
Cost-Effectiveness in Health and Medicine (USPCEHM).62,128
Our effectiveness measures LY and QALY (denominators) were calculated as
follows: since we a weekly cycle for each of therapies, it was important to standardize the
outcome measure LY into a weekly measure.
A constant value of 0.07692 was multiplied by PFS and progression transition
probabilities for all patients who survived (PFS & progressed patients) at each cycle. The
new values of PFS and progression were then discounted after the first year (52 weeks)
and summed to provide a discounted LY gained for each therapy.
In addition, similar steps of Weibull parametric modeling, discounting after 52
weeks and weekly standardization were applied to obtain the QALY of each therapy at
59

each cycle. However, we provided the quality-adjusted life years (QALYs) by
multiplying corresponding utilities by life expectancies. Specifically, we multiplied the
utilities for PFS and progression by the proportion of PFS and progressed patients who
responded to each therapy. We also considered disutilities due to adverse events in the
model by subtracting those disutilities from PFS and progression utility values. We have
finally summed all QALY of progressed and PFS patients at each cycle to yield the
QALY for each therapy.
Health utility values of the three health states and disutility values due to adverse
events were retrieved from published data of EuroQol, Five Dimensions questionnaire
since it provides validated utilities in the US setting.73,129,130 More details about utility
values utilized in the model can be obtained from Table 4. We included utility values of
PFS and progressed patients in the Markov model as well as the disutility values due to
different adverse events from the literature.129,131
Table 4
Health Related Quality of Life (HRQoL) Utility values
Health states utility values
Utility value
Progression-free survival (PFS) of mCRPC patients
0.617
Progression (P) of mCRPC patients
0.37
Death
0

95 % CI
0.55-0.68
0.33-0.41

Reference
120
132
130

Cost Measures
Costs of therapies were obtained from RED BOOK Online® which is a resource
of the latest drug product pricing of over-the-counter and prescription medications in the
US.133 Rates and costs of grade (≥3) adverse events that occurred in (≥5 %) of patients
for the three therapies were obtained from clinical trials, package insert information and
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literature.43,48,51 We have also obtained costs of follow up visits and needed investigations
from the literature.134,135
We included direct medical costs in the model expressed in 2018 US dollars
based on the US healthcare payer perspective, all costs were adjusted for inflation
through the medical consumer price index (MCPI) as per the 1st quarter of 2018.136 We
obtained the wholesale acquisition cost (WAC) of abiraterone, enzalutamide, cabazitaxel
and prednisone from RED BOOK Online®.133 Based on clinical trials and cost data, we
calculated the cost per cycle (7 days) for each therapy or combination of therapy (when
prednisone is given). We have assumed that the default body weight for an adult patient
with mCRPC is 70 kg. Thus, cabazitaxel dose and cost were calculated based on body
surface area of a 70-kilogram patient.43
We have also retrieved costs of grade (≥3) side effects that occurred in (≥5%) of
patients in the model related to each of the therapies from the literature.135,137 These costs
were validated and adjusted based on reported percentages of adverse events by clinical
trials.43,48,51 We have standardized rates and costs of adverse events to a weekly
percentage as reported by clinical trials using the equation (1-(1-p)^(1/52), where P is the
probability of having grade (≥3) adverse events.125
Adverse events
Since clinical trials are conducted under controlled conditions, observed adverse
events rates in clinical trials may not reflect the observed rates in clinical practice or
directly compare to rates in the clinical trials of another drug. Thus, we aimed to include
significant adverse events of grade (≥3) related to each of therapies that occurred in (≥5
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%) of patients based on package insert information and literature since they may have a
significant effect on the course of treatment, survival and costs.50,104
All included grade (≥3) adverse events were retrieved from the clinical trials
COU-AA-301, AFFIRM and TROPIC clinical trials.43,48,51 We have validated reported
percentages by referring to package insert information.
Table 5 provides package insert raw percentages of grade (≥3) adverse events
related to the three therapies. Table 6 describes related adverse events to each of the
therapies, their frequencies, time affected (median exposure) and disutilities as reported
by the clinical trials and literature. The following discussion will explain each of the
therapies adverse events.
Abiraterone acetate plus prednisone
Abiraterone trial (COU-AA-301) included several adverse events of grade (≥3)
associated with the use of abiraterone plus prednisone. However, none of the reported
ones occurred in more than (10%) of patients in the abiraterone plus prednisone arm (the
highest was 9 % associated with fatigue). The median follow-up in the overall study
population was 12.8 months.48
Overall abiraterone was associated with the following grade (≥3) adverse events:
(9 %) fatigue, (1 %) diarrhea, (<3 %) pain in the arm or leg, (7 %) anemia, (<2%)
thrombocytopenia, (<1 %) neutropenia, (<3 %) nausea, (<3%) vomiting, (<1%)
hematuria, (2%) abdominal pain, (<2%) dyspnea, (4%) arthralgia, (2 %) urinary tract
infection and (<5 %) bone pain.48,104
Grade 3-4 arrhythmias occurred at similar rates in the placebo and abiraterone
arms. Cardiac ischemia occurred in 2 patients in the active arm compared to 1 in the
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placebo arm, cardiac death resulting in death occurred in 1 patient in both arms. Since
rates of cardiovascular events were comparable in both arms, we did not include any of
these adverse events and related cost data in the model. In addition, all grade (≥3) cardiac
adverse events (i.e., ischemic heart disease, myocardial infarction, supraventricular
tachyarrhythmias, ventricular tachyarrhythmias, cardiac failure, and possible arrhythmiarelated tests, signs, and symptoms) associated with the use of abiraterone plus prednisone
occurred in 4 % of patients.48
In summary, based on the above reported percentages of related adverse events to
abiraterone plus prednisone, we decided to include costs of anemia, fatigue, diarrhea,
neutropenia, back pain and bone pain in the model since they at least occurred in (≥5 %)
of patients receiving either therapies.
Enzalutamide
Grade (≥3) adverse events were reported among (47 %) of enzalutamide-treated
arm and (53 %) of placebo-treated arm. Additionally, about (18 %) of placebo-treated
patients and (16 %) of enzalutamide-treated patients discontinued the medication. The
median duration of follow up was 14.4 months.51
Most of enzalutamide-treated patients discontinued the drug due to seizure that
occurred (0.9 %). Grade (≥3) enzalutamide-related adverse events were (6 %) fatigue, (1
%) diarrhea and (1 %) musculoskeletal pain. Grade (≥3) seizure, cardiac events and
headache occurred in less than (1 %) of patients.
Overall, we have decided to include reported percentages and costs of fatigue and
diarrhea related to enzalutamide therapy in the model since they at least occurred in (≥5)
% of patients receiving either therapies.
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Table 5
Grade (≥3) Adverse events raw percentages* 138–140
Enzalutamide
(grade≥3)
Fatigue 6 %
Diarrhea 1 %
MS pain 1 %
Headache <1%
CVS <1%
Seizure <1%

Abiraterone plus
prednisone (grade≥3)
Fatigue < 9 %
Diarrhea < 1 %
Arm/leg pain < 3 %
****
Arrhythmias 1 %, Cardiac failure 1.9
% Chest pain 0.5 %
****
Anemia 7 %
Thrombocytopenia <2%
Neutropenia < 1 %
Back pain < 6 %
Nausea <3 %
Vomiting <3 %
Hematuria < 1%
Abdominal pain 2%
Dyspnea < 2%
Arthralgia 4 %
UTI 2 %
Bone pain < 6 %

Cabazitaxel plus
prednisone (grade≥3)
Fatigue < 5 %
Diarrhea 6 %
Arm/leg pain 2 %
****
****
****
Anemia < 11 %
Thrombocytopenia 4 %
Neutropenia < 82 %
Back pain < 4 %
Nausea 2 %
Vomiting 2 %
Hematuria 2 %
Abdominal pain 2%
Dyspnea 1 %
Arthralgia 1 %
UTI 1%
Bone pain 1 %

*Raw percentages as reported by the package insert of each therapy. Note: values shaded in gray
demonstrates all grade (≥3) adverse events included in the model that occurred at least in (≥5) of
patients receiving either of therapies.

Cabazitaxel plus prednisone
We also included grade (≥3) adverse events that occurred in (≥5 %) of patients
who received cabazitaxel plus prednisone as reported by TROPIC trial and package insert
information.140 Cabazitaxel plus prednisone regimen was mostly associated with (82%)
neutropenia, (11 %) anemia, (6 %) diarrhea and fatigue (5 %). Other reported grade (≥3)
adverse events occurred in (<5%) of patients in the cabazitaxel plus prednisone arm as
described in Tables 5 and 6.
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Table 6
Rates and utilities of grade (≥3) adverse events
Drug name

Abiraterone acetate
plus prednisone

Enzalutamide

Cabazitaxel plus
prednisone

Grade (≥3)
Adverse
event

Frequency

Time
affected*

Utility
decrement

Reference

48,131
Anemia
Diarrhea
Fatigue
Back pain
Neutropenia
Bone pain
Fatigue

0.0745
0.0063
0.0834
0.0594
0.0100
0.0590
0.0625

Diarrhea

0.0112

Neutropenia
Anemia
Diarrhea
Fatigue
Back pain
Bone pain

0.8167
0.1051
0.0619
0.0485
0.0377
0.0100

0.00148
0.00012
0.00167
0.00117
0.00390
0.00110
0.00124
0.00021

0.119
0.212
0.473
0.067
0.131
0.067
0.473

48,131
48,131
48
48,131
48
51,131
51,131

0.212
43,129
0.03210
0.00213
0.00123
0.00095
0.00073
0.00390

0.131
0.119
0.212
0.473
0.067
0.067

43,131
43,131
43,131
43
43

*Time affected: All frequencies were converted to a weekly percentage that reflects weekly exposure to the
adverse event using the equation (=1-(1-p) ^ (1/52)), where P reflects the probability/frequency of grade
(≥3) adverse events.125

In summary, costs of fatigue, diarrhea, anemia, neutropenia, back pain and bone
pain associated with abiraterone acetate plus prednisone were included in the model.
Additionally, costs of fatigue, diarrhea, anemia, neutropenia, back pain and bone pain
associated with cabazitaxel plus prednisone; and costs of fatigue and diarrhea associated
with enzalutamide were also included in the model. No further adverse events were
included in the model.
The model included costs of follow up visits and needed procedures obtained
from the Centers for Medicare and Medicaid Services (CMS) physician and clinical
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laboratory fee schedule which is a national pricing reference that uses medical Current
Procedural Terminology (CPT) codes.134,135 We have assumed that all therapies share the
same follow up schedule and needed investigations (weekly physician visit and CBC
check to check for anemia and neutropenia count); and performing CT scan when clinical
or consistent and convincing biochemical progression is identified as recommended in
2017 by the prostate cancer Radiographic Assessment for Detection of Advanced
Recurrence (RADAR) Working Group.141 Based on the above recommendation and due
to the aggressiveness of disease condition, we have assumed that CT scan and home
nurse visits may be performed monthly.
We have also included the 95 % confidence interval estimate for costs of
medications and adverse events to account for uncertainties in cost data. These estimates
were used to conduct probabilistic sensitivity analysis. Table 7 provides more details
related to cost data utilized in the model.
ICER & ICUR calculation
The cost-effectiveness outcome measures were ICER and ICUR expressed as cost
per Life Year (LY) and cost per Quality Adjusted Life Years (QALY) gained for mCRPC
patients as explained in tables (8-11) for the three therapies by dividing the incremental
cost by the incremental effectiveness (LY or QALY) using the formula:
(CostRx1-CostRx2)/ (LY)Rx1-LY) Rx2) and (CostRx1-CostRx2)/ (QALYs Rx1-QALY
Rx2), respectively. Both outcome measures were endorsed as a reference case by NICE
and USPCEHM in the UK.62,128,142
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Table 7
Model Input for Costs
Medications

WAC price per cycle (7 days) *
(95 % CI) **

Reference

Abiraterone acetate 1000 mg
plus, prednisone 10 mg

$2861.614 ($2575.45, $3147.77)

Red Book133

Enzalutamide 40 mg

$2544.54 ($2290.08, $2798.99)

Red Book133

Cabazitaxel 25 mg/m2 plus
prednisone 10 mg***

$8372.94 ($7535.6-$9,210.2)

Red Book133

Adverse events****

Cost of adverse event (95 % CI)

Reference

Fatigue

$6,946.00 ($6251.4, $7640.6)

Roy et al, CMS Acute Inpatient
Prospective Payment System135,137

Diarrhea

$10,760.00 ($9684, $11836)

Roy et al, CMS Acute Inpatient
Prospective Payment System135,137

Anemia
$1,038.00 ($934.2, $1141.8)

Roy et al, CMS Acute Inpatient
Prospective Payment System135,137

Back pain

$10,914.00 ($9822.6, $12005.4)

Roy et al, CMS Acute Inpatient
Prospective Payment System135,137

Neutropenia

$165.00 ($148.5, $181.5)

Roy et al, CMS Acute Inpatient
Prospective Payment System135,137
Reference

Costs of follow up
Costs

Physician visit

$25.74 ($23.1-$28.3)

CMS physician service fee, clinical
laboratory fee schedule search134,135

Complete blood count

$76.14 ($68.5-$83.7)

CMS physician service fee, clinical
laboratory fee schedule search134,135

CT Scan

$230.98 ($207.8-$254)

CMS physician service fee, clinical
laboratory fee schedule search134,135

Home nurse visit

$44.78 ($40.3-$49.8)

CMS physician service fee, clinical
laboratory fee schedule search134,135

*The cost of cycle was calculated by multiplying the cost of each unit by the dose required per day by 7.
** Sensitivity analyses were performed by utilizing the assumed 95% Confidence Interval (CI).
*** The dose of cabazitaxel was calculated based on body surface area of a 70-kilogram patient.
****We have included grade III and above reported adverse events for each therapy in clinical trials. The unit costs for
adverse events were obtained from published sources. Note: Both of adverse events and follow up visits costs were
inflated to 2018 US dollars using the medical care component of the US Bureau of Labor Statistics Consumer Price
Index.
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Since it was recommended by the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) guideline to provide the lowest cost treatment for each
treatment comparison, we provided our cost-effectiveness outcome measures ICER and
ICUR for each therapy starting with the lowest cost.143,144 Base-case (deterministic)
results of outcome measures were validated using probabilistic sensitivity analysis, which
will be discussed in detail in a later section in this chapter.
Table 8
Base case (deterministic) results of the cost-effectiveness analysis
ENZ*
$US/LY gained
ABI+P**
$US/LY gained
$US /LY gained
CAB+P***
*ENZ: Enzalutamide ** ABI+P: Abiraterone plus prednisone ***CAB+P: Cabazitaxel plus prednisone

Table 9
Probabilistic results of the cost-effectiveness analysis
ENZ
$US/LY gained
ABI+P
$US/LY gained
$US/LY gained

CAB+P

Table 10
Base case (deterministic) results of the cost-utility analysis
ENZ
$US/QALY gained
ABI+P
$US/QALY gained
$US/QALY gained

CAB+P

Table 11
Probabilistic results of the cost-utility analysis
ENZ
$US/QALY gained
ABI+P
$US/QALY gained
$US/QALY gained

CAB+P

Since cost-effectiveness of a health technology compared to an alternative is often
determined if the ICER/ICUR falls below a specific threshold, we have considered a
maximum value of $100,000 per QALY to determine if it is cost-effective as
recommended by the Second Panel of Cost-Effectiveness in Health and Medicine.62
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Probabilistic sensitivity analysis
Probabilistic sensitivity analysis produces unbiased estimates of costeffectiveness mean.129 We performed this analysis since it identifies sources of parameter
uncertainty, characterizes uncertainty as probability distributions (e.g. beta & gamma
distributions) and propagates it through model simulation.
Probabilistic sensitivity analysis utilizes values from the Weibull distributions of
OS, PFS, beta distribution of probabilities and utility estimates; and the gamma
distribution of monetary inputs to provide an estimate of effects and costs through
simulation. For example, since costs are expressed in positive numbers, gamma
distribution was applied to address uncertainty in costs. The distribution considers the
average cost per milligram and body surface area if applicable (e.g. cabazitaxel).
Beta distribution was applied to the proportion of patients who responded to the
treatment with abiraterone acetate plus prednisone, cabazitaxel plus prednisone and
enzalutamide. Beta distribution are often indicated for presenting uncertainty in
probability parameters constrained within 0-1. In addition, beta-distribution was applied
to manage uncertainty about the probability of adverse events for patients who received
treatment and for both health-related quality of life utilities and disutilities.
We ran a probabilistic sensitivity analysis with 2,000 iterations to evaluate the
combined effects of uncertainty in all model inputs, assess the robustness of deterministic
base-case analysis and create the cost-effectiveness acceptability curve (CEAC) at
various willingness to-pay thresholds (WTP).
Table 12 provides more details regarding model inputs that were validated
through probabilistic sensitivity analysis.
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Human subjects’ approval
This study was approved by University of New Mexico Health Sciences Center
(UNMHSC) Human Research and Review Committee (HRCC) under the exempt
category. The approval letter is provided in Appendix B.
Table 12
Model Input of probabilistic sensitivity analysis
Parameters
Utility values
Utility value of PFS
Utility value of progressed patients
Disutility value due to adverse event

Costs of therapy
Cost of 7 days cycle of Enzalutamide
Cost of 7 days cycle of Abiraterone
acetate plus prednisone
Cost of 7 days cycle of Cabazitaxel plus
prednisone
Costs of adverse events
Fatigue
Diarrhea
Anemia
Back pain
Neutropenia
Costs of follow up
Weekly Physician visit
Weekly CBC
Monthly CT Scan
Monthly Home nurse visit

Deterministic

Probabilistic Sensitivity Analysis
Range of Values (+/-) 10 %

0.617
0.37
Varies based on
Specific adverse
events

0.55-0.68
0.33-0.41
Varies based on specific adverse
events, please refer to table (6).

$2544.54
$2861.614

($2290.0-$2798.9)
($2575.4-$3147.7)

$8372.94

($7535.6-$9,210.2)

$6,946.00
$10,760.00
$1,038.00

($6251.4-$7640.6)
($9684-$11836)
($ 934.2-$1141.8)
($9822.6-$12005.4)

$10,914.00
$165.00

($148.5-$181.5)

$25.74
$76.14
$230.98
$44.78

($23.1-$28.3)
($68.5-$83.7)
($207.8-$254)
($40.3-$49.8)
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CHAPTER 4: RESULTS
Introduction
This chapter consists of five sections. In the first section, we discuss results of
effectiveness measures which include results of overall survival and progression-free
survival probabilities of enzalutamide, abiraterone acetate plus prednisone and
cabazitaxel plus prednisone obtained from our life-time horizon Markov model. In the
second section, we will discuss base-case results of cost measures This will be followed
by a discussion of the calculation and comparison of the incremental cost-effectiveness
ratios associated with each of the therapies. Fourth, we will discuss results of
probabilistic sensitivity analysis. Finally, we will be providing a summary of study results
in the last section.
Results of Effectiveness measures and Survival Rates
The objective of this study was to estimate the cost-effectiveness between
enzalutamide, abiraterone acetate plus prednisone and cabazitaxel plus prednisone for the
treatment of visceral mCRPC patients who progress despite docetaxel therapy from a US
health care perspective using life-time horizon Markov model.
Figures 6 & 7 provide the results of extrapolated survival curves of abiraterone
acetate plus prednisone, enzalutamide and cabazitaxel plus prednisone using Weibull
parametric modeling of phase III clinical trials OS and PFS curves. Results show that
almost all visceral mCRPC patients are expected to die within 5 years which indicates the
aggressiveness of the disease condition. Specifically, about (98.7 %) of patients who
receive abiraterone acetate plus prednisone, (83.8 %) who receive
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Figure 6
Overall survival (OS) Weibull distribution
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Figure 7
Progression-Free Survival (PFS) Weibull distribution
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cabazitaxel plus prednisone and (86.8 %) who receive enzalutamide are expected to die in
3 years. Additionally, in 1.5 years’ time, patients who receive enzalutamide will have
significantly higher rates (14.47 %) of PFS than cabazitaxel plus prednisone (0.27 %) and
abiraterone acetate plus prednisone (0.51 %).
Overall, patients who receive enzalutamide have higher survival rates (1.58 LYG)
compared to abiraterone plus prednisone (1.20 LYG) and cabazitaxel plus prednisone
(1.48 LYG). However, abiraterone acetate was associated with better quality of life or
outcomes (0.58 QALY) compared to cabazitaxel plus prednisone (0.56 QALY) due to a
better side effect profile.
Base-case results of total cost measures
Our CEA utilized a US healthcare payer perspective. Therefore, we included
direct medical costs in the model expressed in 2018 US dollars. All model costs were
adjusted for inflation through the MCPI as per the 1st quarter of 2018 and future costs
were discounted at 3 %.62,136 We considered costs of drugs per cycle and grade (≥3)
adverse events associated with abiraterone acetate plus prednisone, enzalutamide and
cabazitaxel plus prednisone. We also included costs of physician follow-up visits, blood
work and imaging studies (i.e. monthly CT) based on RADAR and NCCN
recommendations for all visceral mCRPC patients receiving either therapies. Table 13
provides costs of enzalutamide, abiraterone acetate and prednisone whereas table 14
provides results of cabazitaxel since it poses different dosing profile. Table 15 explains
base-case total cost measures of visceral mCRPC therapies.
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Table 13
Costs of enzalutamide, abiraterone acetate and prednisone
Type of
Strength (mg)
WAC price
Dose required
therapy
per tablet
daily
Enzalutamide
40 mg
$90.87
160 mg
Abiraterone
250 mg
$85.26
1000 mg
acetate
Prednisone**
10 mg
$67.73
10 mg

Cost per dose
required daily*
$363.5
$341.0
$67.73

*Cost per dose required daily equals to number of tablets required daily times Wholesale
Acquisition Cost (WAC). **Cost of prednisone represent the average WAC price for multiple
generic products

Table 14
Cost of Cabazitaxel
Body Surface Area
Strength
Dose required
Number of units
Cost per unit
Cost per dose required every 3 weeks

1.75
60/1.5 ml
25 mg/m2
1
$10182.48
$7424.725*

*Cost per dose required (every 3 weeks) assuming no wastage

Table 15
Base-case total cost measures of visceral mCRPC therapies
Type of
Cost
Cost of
Costs of
Costs of followtherapy
per
therapy
grade (≥3)
up visits and
dose
per cycle
adverse
needed
required
events per
investigations
daily
cycle
per cycle
Enzalutamide
$363.50 $2544,54
$555.175
$377.64
Abiraterone
$408.80 $2861,61
$1373.49
$377.64
acetate plus
prednisone
Cabazitaxel
***
$8372.94
$1659.78
$ 377.64
plus
prednisone
***Cabazitaxel plus prednisone dose is given every 3 weeks.
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Total costs

$157,830
$235,854

$496,756

Calculation and comparison of the incremental cost-effectiveness(ICERs) and
incremental cost-utility ratios (ICURs) associated with each of the therapies
We estimated the cost-effectiveness [cost per LYG] and cost-utility analyses [cost
per QALY] of visceral mCRPC therapies in patients who progress despite docetaxel
chemotherapy from a US healthcare payer perspective using a life-time horizon Markov
model.
Table 16 presents the base-case results of total LYG and QALY gained.
Enzalutamide was found to be more effective (1.58 LYG) compared to abiraterone plus
prednisone (1.20 LYG) and cabazitaxel plus prednisone (1.48 LYG). Additionally,
Enzalutamide was associated with higher total QALY, (0.79 QALY), compared to
abiraterone plus prednisone (0.58 QALY) and cabazitaxel plus prednisone (0.56 QALY).
Enzalutamide was also associated with lower total costs ($157,830) compared to
abiraterone acetate plus prednisone ($235,854) and cabazitaxel plus prednisone
($496,756).
Table 16
Base-case results of total costs and effectiveness measures
Comparator
ENZ
ABI+P
CAB+P

Total Cost
$157,830
$235,854
$496,756

Total LY gained
1.58
1.20
1.48

Total QALYs gained
0.79
0.58
0.56

ENZ: Enzalutamide, ABI+P: Abiraterone acetate plus prednisone, CAB+P: Cabazitaxel plus prednisone

ICER and ICUR calculation provide the ratio of the incremental difference in
costs divided by the incremental difference in outcomes and used to determine the
magnitude of the added cost for each unit in health improvement. However, based on the
above results, enzalutamide dominated both abiraterone plus prednisone and cabazitaxel
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plus prednisone as it provided more effectiveness at lower costs. Thus, enzalutamide was
found to be cost-effective compared to abiraterone acetate plus prednisone and
cabazitaxel plus prednisone.
However, abiraterone acetate plus prednisone was found to less effective and less
expensive than cabazitaxel plus prednisone and therefore, the ICER and ICUR were
calculated between these two options for the scenario where enzalutamide was not a
dominant option. Cabazitaxel plus prednisone had an ICER & ICUR of $931.7K/LYG
and almost 13 million/QALY respectively when compared to the next lowest treatment,
abiraterone acetate plus prednisone.
Results of probabilistic sensitivity analysis
Probabilistic sensitivity analysis evaluates combined effects of uncertainty of all
model input. This is achieved through repeated sampling of mean parameter values from
a series of assigned distribution types, based on the standard error statistics and point
estimates for each average parameter values. Each set of samples from all parameters
generate a single estimate of expected effects and costs provided by the model.
Gamma distribution is useful to assess uncertainties of monetary inputs since they
are constrained on an interval from zero to positive infinity.145 Thus, we have used
gamma distribution to assess uncertainties in costs of drugs per milligram per cycle and
costs of grade (≥3) adverse events that occurred at least in (≥5%) of visceral mCRPC
patients according to package insert information and phase III clinical trials data. Gamma
distribution was also used to evaluate uncertainties in costs of follow up visits and any
needed investigations as discussed in table 6.
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Beta distribution was used to evaluate uncertainties in HRQoL utility estimates
since they present uncertainty in probability parameters constrained between 0-1.129 Beta
distribution was also used to evaluate uncertainties in disutility values of grade (≥3)
adverse events that occurred at least in (≥5%) of visceral mCRPC patients.
The analysis was run over 2000 iterations, at which point we evaluated the impact
of further simulations on the mean probabilistic sensitivity analysis results. The results
were also used to create the cost-effectiveness acceptability curve (CEAC).
Scatter plots were generated using Microsoft Excel® supported by macros and
functions showing the four-quadrant plane that assesses the cost-effectiveness measures
associated with abiraterone acetate plus prednisone, enzalutamide and cabazitaxel plus
prednisone. Additionally, CEAC were plotted to show the probability of the three
therapies to be cost-effective at various WTP thresholds. Figure 8. represent the
probabilistic sensitivity analysis cost-effectiveness plane, which demonstrates the
incremental costs and QALY difference between therapies. Figure 9. and 10. represent
the CEAC for visceral mCRPC therapies. Enzalutamide dominated both therapies.
Additionally, cabazitaxel plus prednisone becomes cost-effective compared to
abiraterone plus prednisone (50 % cost-effective point estimate) at 12 million
$US/QALY. Although the three therapies exceeded $100,000/QALY which is the
recommended WTP threshold for cost-effectiveness by the second panel of costeffectiveness in health and medicine, payers should be informed about these results and
decide about payment conditions.
Table 17 presents the average reading of probabilistic sensitivity analysis results
for both total costs and effectiveness measures for all visceral mCRPC therapies. Results
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show that probabilistic sensitivity analysis are very comparable to base-case results
which indicates that our base-case estimates are robust.
Table 17
Probabilistic sensitivity results of total costs and effectiveness measures
Comparator
ENZ
ABI+P
CAB+P

Total Cost
$157,903
$235,741
$496,370

Total LYG
1.58
1.20
1.48

Total QALYs
0.79
0.58
0.56

ENZ: Enzalutamide, ABI+P: Abiraterone acetate plus prednisone, CAB+P: Cabazitaxel plus prednisone

Figure 8
Probabilistic sensitivity analysis cost-effectiveness plane*
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Figure 9
Cost-effectiveness acceptability curve*
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Figure 10
Cost-effectiveness acceptability curve*
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CHAPTER 5: DISCUSSION
This chapter consists of seven sections. In the first section, we will discuss the
interpretation of the findings of our study. In the second section, our findings are
compared to previous literature. This will be followed by discussing study’s implications
in the third section. Fourth, we will discuss the strengths of our study. Limitations of our
study are discussed in the fifth section. This will be followed by discussing area of future
research in the sixth section. Finally, we will close this chapter by providing a conclusion
in the last section.
Interpretation of study findings
As recommended in the ISPOR Task Force Report of Consolidated Health
Economic Evaluation Reporting Standards (CHEERS), [which provides
recommendations in a checklist format to optimize reporting of health economic
evaluations]; we discuss key findings of our study and describe how they support the
conclusions reached as well as discuss limitations, generalizability of study findings and
how findings fit with the current knowledge.146
Prostate cancer creates a substantial medical and non-medical burden. In 2006,
nearly US $9.9 billion was spent on prostate cancer in the United States, increasing to US
$11.9 billion in 2012, US $13.4 billion in 2014 and expected to reach US $15.4 billion by
2020; making prostate cancer the fifth most costly cancer.7–9 There are several important
clinical and economic implications for utilizing newer therapeutic options that show
improved survival and minimize cost.
As cancer-related healthcare expenditures are increasing, the ASCO Value in
Care Task Force proposed a framework to evaluate the value of new cancer drugs versus
80

standard of care treatments. The framework integrates incremental and nominal clinical
benefit of cancer treatment with toxicity to determine the net health benefit, then
compared against the cost of treatment.7,8,147
Visceral mCRPC is considered one of the major cancers with high cancer-related
mortality rates. Our results have showed that almost all visceral mCRPC patients are
expected to die within 5 years, which indicates the aggressiveness of the disease
condition. Although docetaxel plus prednisone chemotherapy remains the gold standard
therapy to treat those patients, most patients will progress and become resistant to
chemotherapy, which mandates the initiation of novel treatments recommended by
NCCN.6
Several controversial aspects related to prostate cancer management exist since
limited data are available to support treatment recommendations. Many variables like
predicted outcomes, patient clinical characteristics and preferences; and adjusted life
expectancy should be considered by the healthcare provider and patient to tailor treatment
according to patient clinical conditions, preferences and values.6,20,21,23,38
According to the 2017 NCCN guidelines, there is still no agreement for the best
therapy for patients with visceral mCRPC who progress after docetaxel therapy.
Available therapeutic options include enzalutamide, abiraterone acetate plus prednisone
and cabazitaxel plus prednisone. These therapies received NCCN highest level of
recommendations to treat patients with visceral mCRPC. Other therapeutic options like
radium-223 and sipuleucel-T are not indicated for patients with visceral metastasis.
The decision to start treatment for patients who progress after docetaxel should be
based on high level of efficacy and safety evidence as well as patient tolerability toward
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therapy and potential side effects.148–150 To our knowledge, there is no supportive data to
inform the sequence for delivery of these treatments as there were no randomized headhead clinical trials have been reported. Additionally, no biomedical makers are available
to help identify patients who are likely to benefit from any of these treatments.
Patients who are started on any of the treatments should be closely monitored for
any signs of flare or evidence of clinical progression. NCCN and RADAR recommend
periodic laboratory investigations (e.g. CBC, PSA tests) and radiological imaging to
check for evidence of disease progression.6,141
Based on the above discussion, we aimed to estimate the cost-effectiveness of
enzalutamide, abiraterone acetate plus prednisone and cabazitaxel plus prednisone for the
treatment of visceral mCRPC patients who progress despite docetaxel therapy from a US
health care perspective using life-time horizon Markov model.
Healthcare economic evaluations are conducted to inform healthcare resource
allocation which has been defined as “the comparative analysis of alternative courses of
action in terms of both their costs and consequences”.62 CEAs in healthcare are
conducted to provide decision makers with supplemental information that may be helpful
in supporting their decision about introducing, maintaining or assessing health
technologies. CEAs provide comparative efficacy, safety and cost information related to
health technologies being considered for the study.
Model-based CEA uses estimates of effects and costs from various sources,
including retrospective databases (e.g. claims databases), observational studies,
randomized controlled trials and meta-analyses to extend the analysis beyond clinical
trials contrived settings and time frame to estimate ultimate outcomes and cost82

effectiveness. For example, model-based CEA may estimate costs and outcomes of
measures not fully captured by the clinical trials horizon such as QALY and length of
life. Decision analytic models are also useful in weighing outcomes and costs as well as
assessing implications of evidential and other forms of uncertainty of decisions.62
Since clinical trials provide evidence regarding efficacy testing, there is still a
need to translate clinical effectiveness endpoints into measures that are valued and crucial
for different stakeholders. Our economic model utilized OS and PFS survival data, to
extrapolate and generalize survival data beyond clinical trials time horizon to evaluate
how therapies work in real-world practice. Both of outcomes and costs may be different
under clinical trials conditions compared with when used in the general population. Thus,
the results may provide physicians, decision makers and healthcare payers valuable
information to make appropriate treatment and payment decisions. Since our study is
from a US healthcare perspective, different US payers may use our CEAs results as a
supplemental tool to decide on coverage/reimbursement decisions as results can be
utilized by any payer and results can be generalized to different US healthcare payers.
Our literature review identified no studies that conducted an economic evaluation
of abiraterone acetate, enzalutamide and cabazitaxel to treat visceral mCRPC patients’
refractory to docetaxel therapy from a US healthcare payer perspective utilizing a
Markov model. However, several economic evaluations compared different treatment
paradigms for mCRPC, or had a different perspective (e.g. societal), or targeted different
patient population, or utilized a different methodology (e.g. decision tree model) to
inform decision makers or had a shorter time-horizon or were in non-US settings.9,64–77
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Our Markov model included three-health state (PFS, progression and death)
transition model reflecting survival. Given the short life expectancy of visceral mCRPC,
we employed a life-time horizon Markov model. The patient who starts at the PFS health
state may stay in the same health state until the next cycle or progress or die. However, a
patient with disease progression may either stay at the same state until the next cycle or
improve and go back to PFS or die. Since mCRPC disease management and
complications develop at a relatively fast time scale, a cycle of 7 days length was
considered for cost-effectiveness modeling of mCRPC therapies.73,125
A (3%) discounting was applied for all patients who survived (PFS and
progressed patients) after the first year (52 weeks) as recommended by the US Panel on
Cost-Effectiveness in Health and Medicine.62
Overall, results of our life-time horizon Markov model which estimated survival
rates of visceral mCRPC patients showed that patients who receive enzalutamide will
have higher OS and PFS rates (1.58 LYG) at total costs of ($157,830) compared to
abiraterone plus prednisone (1.20 LYG) at total costs of ($235,853) and cabazitaxel plus
prednisone (1.48 LYG) at total costs of ($496,756).
To interpret the findings of our study, enzalutamide was found to be cost-effective
therapy compared to abiraterone acetate plus prednisone and cabazitaxel plus prednisone.
Enzalutamide was associated with + 0.38 LYG compared to abiraterone acetate plus
prednisone and + 0.10 LYG compared to cabazitaxel plus prednisone. Additionally,
enzalutamide was associated with + 0.21 QALY compared to abiraterone acetate plus
prednisone and + 0.23 QALY compared to cabazitaxel plus prednisone. We believe that
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cabazitaxel plus prednisone was associated with least number of QALY because of larger
associated grade (≥3) adverse events profile compared to other therapies.
Additionally, since abiraterone acetate plus prednisone was found to less effective
(1.20 LYG) and less expensive ($235,853) than cabazitaxel plus prednisone (1.48 LYG)
at total costs of ($496,756), cabazitaxel plus prednisone had an ICER & ICUR of
$931.7K/LYG and almost 13 million/QALY respectively when compared to the next
lowest treatment, abiraterone acetate plus prednisone.
Although Cabazitaxel plus prednisone was associated with higher total LYG
compared to abiraterone, it was associated with 3.14 times higher total costs than
enzalutamide and 2.1 times higher total costs than abiraterone acetate plus prednisone.
We believe that the total costs of cabazitaxel plus prednisone was higher due to higher
costs of drug per cycle and grade (≥3) adverse events.
Specifically, cabazitaxel plus prednisone was associated with 3.3 and 2.9 times
higher drug costs per cycle than enzalutamide and abiraterone acetate plus prednisone
respectively. Additionally, cabazitaxel plus prednisone was associated with 2.98 and 1.2
times higher costs of adverse events per cycle compared to enzalutamide and abiraterone
acetate plus prednisone respectively mostly because of higher neutropenia events. Costs
of physician follow up and needed investigations were similar across the three therapies
because we have assumed that all visceral mCRPC patients will have comparable
treatment plan and follow up schedule (e.g. weekly CBC, PSA test, monthly CT scan and
home visit).
Results of probabilistic sensitivity analysis are very comparable to base-case
results which favor the robustness of base-case estimates. CEACs showed that
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enzalutamide dominated both therapies, and cabazitaxel plus prednisone becomes costeffective compared to abiraterone acetate plus prednisone at 12 million $US/QALY.
Although the three therapies exceeded $100,000/QALY which is the recommended WTP
threshold for cost-effectiveness by the Second Panel of Cost-effectiveness in Health and
Medicine, payers should be informed about these results and decide about payment
conditions. Additionally, since we utilized an economic model to estimate the costeffectiveness of visceral mCRPC therapies, we have utilized several assumptions to
indicate the value for money of our interventions and therefore, economic models are
subjected to problems and errors. However, they can still be valuable input for decision
makers. The use of rigid cost-effectiveness threshold to determine funding decisions may
encourage interested parties to tailor their estimates to trigger funding. On the other hand,
we cannot leave our patients without getting appropriate evidence-based novel therapies
that show improved survival rates. Therefore, our study results may be used to inform
coverage/reimbursement decisions in this therapy area.
Overall, the greater economic benefit in terms of cost-savings and total costeffectiveness and cost-utility favor enzalutamide therapy. Since our study is from a US
healthcare perspective, this analysis should not be generalized to other settings or
healthcare financing systems and countries. In addition, our economic evaluation intends
to inform healthcare payers and policy makers – not to set policy or guide clinical
practice. The following section will compare our study to previous literature.
Comparison with previous literature
Our literature review identified 16 economic evaluations. However, no studies
were identified that conducted an economic evaluation of abiraterone acetate,
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enzalutamide and cabazitaxel to treat visceral mCRPC patients’ refractory to docetaxel
therapy from a US healthcare payer perspective utilizing a Markov model. However,
several economic evaluations compared different treatment paradigms for mCRPC, or
had a different perspective (e.g. societal), or targeted different patient population, or
utilized a different methodology (e.g. decision tree model) to inform decision makers or
had a shorter time-horizon or were in non-US settings. In addition, to our knowledge, our
study is the first one that evaluated the above mentioned therapeutic agents from a US
healthcare payer perspective. Specifically, the review included only two articles that were
close to our research question. Wilson et al (2014) conducted CEA of abiraterone acetate,
enzalutamide and cabazitaxel compared to placebo (prednisone). However, it had a shorttime horizon (18 months), considered QALY only as an effectiveness measure, utilized a
decision-tree model with no discounting considered due to short-time horizon. Results
showed that abiraterone acetate provided total QALY of 0.70 at total costs of $116,700.
Enzalutamide provided total QALY of 0.73 at total costs of $129,769 and Cabazitaxel
provided 0.76 of total QALY at total costs of $136,979. None of the therapies was
dominant and the ICER for enzalutamide when compared to the next lowest treatment,
abiraterone, is $437.6 K/QALY. Cabazitaxel had an ICER of $351.9K/QALY when
compared to the next lowest treatment, enzalutamide. None fell below the generally
accepted WTP threshold of $100,000 per QALY. They concluded that abiraterone is the
most cost-effective treatment compared to placebo and other therapies.68
Although Peters et al (2016) included the three therapies of interest in addition to
radium-223 which is not indicated to treat visceral mCRPC, it utilized a Markov model
and had a life-time horizon (5 years). However, it was a Dutch economic evaluation from
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a societal perspective. 56,73 Results of the study were more comparable and showed that
radium-223 provided a total of 0.8 QALY and 1.39 LYG compared to 0.86 QALY and
1.5 LYG with enzalutamide, 0.78 QALY and 1.36 LYG with abiraterone; and 0.79
QALY and 1.38 LYG with cabazitaxel. However, enzalutamide was associated with
higher total costs (€85,000) compared to (€84,410) with abiraterone acetate and
(€82,783) with cabazitaxel.
Overall, since discussed articles did not conduct a comparative CEA of the three
therapies of visceral mCRPC from a US healthcare perspective utilizing life-time Markov
model, our economic evaluation will add to the previous efforts of published economic
evaluation. The following section will discuss study’s implications.
Study implications
The main objective of conducting CEA is exploring efficient ways for allocation
of resources. In the light of currently available data, our results indicate the use of
enzalutamide from a US healthcare payer perspective to treat visceral mCRPC patients
post docetaxel failure as it provided higher total effectiveness at lower costs and
dominated the other two therapies in our CEA. Enzalutamide dominated both abiraterone
acetate and cabazitaxel plus prednisone in our CEA. In addition, from patient perspective,
enzalutamide is associated with fewer grade (≥3) adverse events and therefore, poses
better tolerability and safety profile compared to other therapies.
Study Strengths
Our study provides valuable information and adds a unique contribution to current
knowledge of recommended visceral mCRPC treatments.

88

Our study has several strengths in comparison to previously published economic
evaluations. Results of literature review identified no studies that conducted an economic
evaluation of abiraterone acetate, enzalutamide and cabazitaxel to treat visceral mCRPC
patients’ refractory to docetaxel therapy from a US healthcare payer perspective utilizing
a Markov model. However, several economic evaluations compared different treatment
paradigms for mCRPC, or had a different perspective (e.g. societal), or targeted different
patient population, or utilized a different methodology (e.g. decision tree model) to
inform decision makers or had a shorter time-horizon or were in non-US settings.9,64–77
Therefore, to our knowledge, our study is the first one that estimated the costeffectiveness of enzalutamide, abiraterone acetate plus prednisone and cabazitaxel plus
prednisone for the treatment of visceral mCRPC after docetaxel therapy from a US
healthcare perspective using life-time horizon Markov model.
In addition, since our study utilized phase III clinical trials data that provide
evidence regarding efficacy testing, our study aimed to translate clinical effectiveness
endpoints into measures that are valued and crucial for different US healthcare payers
since both of outcomes and costs may be different under clinical trials conditions
compared with when used in the general population. US healthcare payers may use our
CEAs results as a supplemental tool to decide on coverage and reimbursement decisions
as results can be utilized by any payer and results can be generalized to different US
healthcare payers.
We also employed a life-time horizon Markov model as we believe visceral
mCRPC is a complex and dynamic disease and people can move back and forth within
different health states within a short time given the short expectancy of visceral mCRPC
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patients. Other published economic evaluations adopted other decision analytic models
like (e.g. decision tree) or considered shorter time horizon which would be more feasible
in other disease conditions.
Study limitations
Although our study is the first to estimate the cost-effectiveness of visceral
mCRPC therapies from a US healthcare perspective using life-time horizon Markov
model, it has several limitations.
First, sampling uncertainty may exist in our study results since we obtained
clinical efficacy data and rates of adverse events from COU-AA-301, AFFIRM and
TROPIC phase III clinical trials. However, this issue was addressed by reporting the (95
%) confidence interval around point estimates for average costs of drugs, grade (≥3)
adverse events; and follow up visits and investigations and utility estimates; and followed
by conducting probabilistic sensitivity analysis for all model inputs to assess the
robustness of base-case results and create the CEAC at various WTP thresholds.
Second, we only included adverse events of grade (≥3) that occurred at least in 5
% of visceral mCRPC patients who received either therapies in the model because they
are associated with significant costs and may have greater impact on patient quality of
life. Moreover, our economic model aimed to estimate the cost-effectiveness of visceral
mCRPC therapies without inflating or underestimating costs of adverse events since all
addressed medications were associated with a wide range of common adverse events of
any grade (≥10%) addressed in the literature review chapter and this may not happen in
real-world practice.
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Third, although abiraterone acetate plus prednisone was associated with severe
cardiovascular events, COU-AA-301 clinical trial did not explicitly provide categorized
frequencies for various cardiovascular events. In addition, since rates of cardiovascular
events were comparable in placebo and abiraterone plus prednisone arms, we did not
include any of these adverse events and related cost data in the model. In addition, all
grade (≥3) cardiac adverse events that included (ischemic heart disease, myocardial
infarction, supraventricular tachyarrhythmias, ventricular tachyarrhythmias, cardiac
failure, and possible arrhythmia-related tests, signs, and symptoms) associated with the
use of abiraterone plus prednisone occurred in 4 % of patients whereas, we determined a
cut-off of 5 % for all grade (≥3) adverse events to be included in the model.48
Fourth, we assumed costs of follow-up visits and needed investigations are similar
across different visceral mCRPC therapies. One may argue that patients who receive
cabazitaxel plus prednisone would incur more physicians ‘office visits to receive
treatment due to adverse events. Nonetheless, from the published literature, we did not
find any evidence of the differences in the number of physicians’ office visits between
different therapies. Additionally, drop-out rates reported in COU-AA-301, AFFIRM and
TROPIC trials due to adverse events were comparable. Specifically, drop-out rates for
patients were 19 %, 18 % and 13 % for abiraterone acetate plus prednisone, cabazitaxel
plus prednisone and enzalutamide respectively.43,48,51 Thus, assumptions of equal number
of physicians’ office visits; CBC and PSA tests; and home nurse visits and CT scan was
made for the purpose of our study. However, we determined number of visits and
investigations based on RADAR recommendations.141
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Fifth, our study did not consider the effect of different dosing of drugs due to
potential differences in disease severity, patients’ previous experience, preferences and
values with any of visceral mCRPC therapies. We have followed treatment guideline
recommendations with regards to initiating treatment post-docetaxel failure.
Sixth, although our study is from a US health perspective, we utilized a utility
value of grade (≥3) anemia adverse events from NICE since we could find a relative one
in the US setting. In addition, despite other utility values of adverse events were retrieved
from published literature in the US setting, some of them were for different disease state
(e.g. metastatic pancreatic cancer), although one may argue that utility values of adverse
events would be the same regardless of the disease condition.
Finally, overall limitation of conducting a pharmacoeconomic study is using
multiple components of evidence (e.g. clinical trials) and making assumptions to
construct the model. In addition, study results are only as good as the components
representing the truth or reality that are part of the model (i.e., if one of the probabilities
or costs estimates were very wrong, it could have a huge impact on the model and CEA
results).
Area of future research
The Second Panel of Cost-Effectiveness in Health and Medicine recommended
that all studies report a reference case analysis based on healthcare sector perspective and
another reference case based on societal perspective. 62 Reference cases should be defined
by resources and components to consider for evaluation, methods to use and elements for
reporting. To enhance consistency and comparability across studies, it is important to
standardize methods and components within a perspective.62 Thus, future areas of
92

research conducted from societal perspective to compare visceral mCRPC therapies after
docetaxel therapy may be helpful to different stakeholders because of inclusion of
mCRPC therapies costs to the society in the analysis as well as utilization of societal
health utility values rather than of the healthcare payer. In general, conducting the study
from a societal perspective may or may not change cost-effectiveness order of
medications. Including societal costs and health utility values may have a significant
impact on total costs and QALY estimates. However, they may not change costeffectiveness order of medications in our study because cabazitaxel plus prednisone is the
most expensive drug and causes wider range of side effect profile. Enzalutamide costs
less and associated with least side effect profile.
Since cost-effectiveness analysis of health technologies may vary across different
settings and countries because of differences in the incidence and severity of disease
condition, clinical practice pattern, the availability of healthcare resources and relative
prices of healthcare, we believe that conducting the study using the same methodology
and patient population in different settings may be helpful in informing different
stakeholders across different countries.151,152
Conclusion
We estimated the cost-effectiveness of enzalutamide, abiraterone acetate plus
prednisone and cabazitaxel plus prednisone for the treatment of visceral mCRPC postdocetaxel failure from a US healthcare perspective using life-time horizon Markov
model. In general, we found that enzalutamide is cost-effective compared to abiraterone
acetate plus prednisone and cabazitaxel plus prednisone in the US setting.
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Specifically, enzalutamide dominated other therapies and provided higher total
effectiveness (1.58 LYG and 0.79 QALYs) at lower total costs ($157,830). Further,
abiraterone acetate plus prednisone provided less total effectiveness (1.20 LYG) at lower
total costs ($235,853) compared to cabazitaxel plus prednisone (1.48 LYG at total costs
of $496,756).
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